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Towards the goal of novel β-peptide synthesis, a method to access a variety of enantioenriched 
β-amino acid precursors was developed.  These β-amino acid precursors were then utilized in the 
synthesis of numerous β-peptides in solution and on solid support.  The β-amino acid precursors 
allowing this unique technology are thiazinone and β-lactam heterocycles which were accessed 
via asymmetric cycloadditions of N-acyl imines and ketenes utilizing cinchona alkaloid catalysts.  
The methodology developed herein provides access to unique and previously unavailable β-
amino acids and β-peptides.  
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BOC…………………………………………………………………………tert-Butyloxycarbonyl 
CBZ……………………………………………………………………………….Carbobenzyloxy  
DMAP…………………………………………………………………..4-Dimethylaminopyridine 
DMF…………………………………………………………………………..Dimethylformamide 
 FMOC……………………………………………………………….Fluorenylmethyloxycarbonyl 
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LYS………………………………………………………………………………………….Lysine 
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SRIF………………………………………………………..Somatotropin release-inhibiting factor 
THF…. ……………………………………………………………………………Tetrahydrofuran 
THR……………………………………………………………………………………...Threonine 
TLC……………………………………………………………………Thin Layer Chromatograpy 
TMS………………………………………………………………………………..Trimethylsilane   
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1.0  INTRODUCTION 
Due to the increased interest in β-amino acids and β-peptides for use in peptidomimetics 
and the limited number of naturally occurring β-amino acids, we worked to develop 
methodology to synthesize these compounds efficiently and with variability.  Inspired by 
asymmetric cycloaddition chemistry already developed within the group, we saw an opportunity 
to prepare heterocycles that could be used as β- amino acid precursors.  We envisioned an 
asymmetric cycloaddition that would provide access to heterocycles that are masked β-amino 
acids that would also mimic natural amino acids.  From the heterocycles, ring-opening and 
deprotection reactions would allow for synthesis of peptides in solution and on solid support.  
We also wanted to ensure that the β- amino acids synthesized from this methodology could also 
participate in traditional peptide coupling reactions and help to add versatility in the synthesis of 
peptidomimetics.   
1.1 ΒETA-AMINO ACIDS IN PEPTIDOMIMETICS 
In the development of drug candidates, peptides are known to have high selectivity 
toward their targeted proteins and can be synthesized efficiently with natural amino acids.  
Unfortunately, what they have in selectivity does not compensate for their poor solubility and 
poor bioavailability. Peptides are recognized and degraded very quickly in the body, often 
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making them inferior drug candidates.  One strategy to access the selectivity of peptides in the 
body but also improve the bioavailability of peptides is to synthesize unnatural peptides that 
mimic the structure and activity of natural peptides such as peptidomimetics and specifically, β-
peptides.  Due to these unique characteristics, β-peptide research has grown considerably in the 
past decade with much of the research devoted to the conformation, biological activity and 
synthesis of β-peptides and their monomers, β-amino acids. 
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Figure 1.  Seebach convention for naming substituted β-amino acids 
 
Observing the structure of β-amino acids compared to α-amino acids (Figure 1), the 
similarity of their structures and increased structural diversity of β-amino acids makes β-amino 
acids very useful in peptidomimetics.  Unfortunately, there are not many β-amino acids produced 
naturally and the synthesis of these compounds can be difficult.  Production of β-amino acids is 
especially rare in mammals, where most of the natural β-amino acids produced are β-alanine, β-
aminoisobutrate or derivatives thereof.  It was observed, however, that bacteria are able to 
produce a variety of β-amino acids1.  There have been several isolated natural products with high 
biological activity that contain β-amino acids such as Dolastatin 11 and Kulokekahilide 1 (Figure 
2). 
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Figure 2.  Natural products, Dolastatin 11 and Kulokekahilide 1 that contain β2,3-amino acids  
 
 
The unique characteristics of the β-amino acid functionality have been recognized and 
utilized in many well-known drugs, including Taxol, penicillin G, cephalosporin C and betastatin 
(Figure 3).  The β-amino acid in Taxol is essential for its microtubule-stabilizing activity2 and 
betastatin’s β-amino acid is critical for active site binding3.  In penicillin G and cephalosporin, 
the β-amino acid motif is present as a β-lactam and is the source of their antibacterial activity.4  
The β-amino acid motif present in these molecules is critical for their high activity which 
showcases the utility of β-amino acids in drug development.  
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Figure 3.  Clinical drugs that have a β-amino acid moiety  
 
The conformation of peptidomimetics and β-peptides has become a very large area of 
research due to the importance of secondary structure on the selectivity and activity towards 
targeted proteins.  Also of importance is their biological activity where β-peptides are more 
resistant to degradation within the body and therefore can provide a longer half-life than their 
analogous α-peptides.  Subsequently, one of the major strategies of peptidomimetics is utilizing 
β-amino acids in the place of natural α-amino acids.  This modification is specifically useful 
when the cleavage site of a peptide is recognized by peptidases within the body and replacement 
of that amino acid with a β-amino acid can effectively prevent the degradation while also 
incorporating the correct substitution on the molecule.  The success of this modification was 
showcased by Gademann et al in the synthesis and biological evaluation of a cyclo β-tetrapeptide 
as a somatostatin analogue5,6.  The natural α-peptide hormone, somatostatin, is important in the 
regulation and release of growth hormone and insulin.  Additionally, sandostatin, 1, a cyclic α-
octapeptide derived from somatostatin is in clinical use but has a very short half-life (90 min)5.  
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Their goal was to synthesize an analogue of this compound that would mimic the activity of the 
original sandostatin as well as provide a longer half-life in the body.  Structure-activity 
relationship studies were done revealing the importance of the (Phe-Trp-Lys-Thr) sequence for 
activity.   To mimic the (Phe-Trp-Lys-Thr) sequence, they synthesized the cyclic β-tetrapeptide, 
2 (Figure 4).  Due to the cyclic structure of the compound, the β-turn site where the major 
binding occurred was enforced in the molecule.  They found that the affinity of 2 was in the 
micromolar range, at least one order of magnitude lower than those of the sandostatin 1.  
Although the affinity for the target protein was not as large as that of sandostatin, it did show 
potential for use of β-peptide compounds in peptidomimetics.   
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Figure 4.  Synthesis of 2 which was designed to mimic 1 
 
Gademann et al. then proposed the synthesis of linear peptides to mimic 2.  They 
believed the linear peptide would adopt the active conformation based on the folding preference 
of β-amino acids themselves and the intramolecular hydrogen bonding that can stabilize these 
structures.  Using the same sequence of β-amino acids as their cyclic tetrapeptide 2, they 
synthesized 3, which they believed would adopt a 10-membered turn stabilized by intramolecular 
hydrogen bonding (Scheme 1).   The synthesized linear peptide 3 showed significant and 
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selective affinity for one of the human SRIF receptors, in which it was 20 times more selective 
than 1, but 20 times lower than 2.  From this case study, it was evident that replacing an α-amino 
acid with a β-amino acid was a very effective method of modifying both the metabolism as well 
as the conformation and selectivity of the peptide.  Due to the success and enormous potential 
success of β-amino acids and β-peptides in peptidomimetics, it is important to have the capability 
to synthesize a large variety of these compounds.    
 
Scheme 1.  Synthesis of linear peptide to mimic cyclic peptide 
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1.2 PREVIOUS CATALYTIC ASYMMETRIC SYNTHESES OF ΒETA2,3-AMINO 
ACIDS 
Critical to the development of β-peptides and peptidomimetics is the synthesis of the 
individual monomers, β-amino acids.  β-amino acids provide incredible potential in 
peptidomimetics due to their similarities to natural amino acids with the advantage of having 
increased diversity from the extra substitution and conformational differences.  With the same 
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functionality as α-amino acids, β-amino acids can also be incorporated into a peptide chain using 
similar peptide coupling reaction conditions.  
Although there have been a variety of methods developed to synthesize β-amino acids1,7 
and there are a number of commercially available β-amino acids, most of the methods require 
stoichiometric chiral auxiliaries or homologation of α-amino acids.  The majority of the easily 
accessible β-amino acids are either β2 or β3-amino acids, while the synthesis and availability of 
disubstituted β2,3-amino acids is more rare.  Mannich-type reactions provide the correct 
connectivity for β-amino acids while also allowing for a diverse substrate scope and 
enantioenriched products, whereby one can control the substitution and stereochemistry about 
the newly formed bond depending on imine and enol substitution as well as the chiral 
environment.  These compounds have been successfully synthesized with a variety of metal 
catalysts and organocatalysts for the formation of the metal enolate and activation of the 
aldehyde, respectively.    
A recent example of a catalyzed Mannich- type reaction resulting in enantioenriched syn-
substituted β2,3-amino acids is the lanthanum aryloxide/ pybox catalyzed Mannich reaction 
developed by Morimoto et al., (Scheme 2).8  In these reactions, a trichloromethyl ketone (5) is 
utilized as the pronucleophile.  These reactions were found to provide good yields, 
diastereoselectivity and enantioselectivity.  In terms of substrate scope, it was found that aryl 
substitution on the imine was superior and only a methyl substitution was attempted on the 
trichloromethyl ketone unit.  The resulting Mannich adduct could also be modified to be useful 
in β-amino acid synthesis.  With solvolysis, the trichloromethyl ketone can be quantitatively 
transformed into a methyl ester, 6.   
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Scheme 2.  Lanthanum aryloxide/pybox catalyzed Mannich reaction by Marimoto et al 
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Copper catalyzed reactions resulting in anti-substituted β-amino acids were developed by 
Suzuki et al.9 They utilized catalytic amounts of a soft Lewis acid [Cu(MeCN)4]PF4 and a hard 
Bronsted base Li(OC6H4-o-OMe) in a Mannich-type reaction with N-Dpp imine (7) (Scheme 3).  
The reactions were found to proceed with good yield and enantioselectivity.  In this reaction, R1 
is limited to H, Me, Et, or Prop and the substitution on the imine is limited primarily to aryl 
groups.  The thioamide functional group of the Mannich reaction product can also be further 
modified.    
Scheme 3.  Copper catalyzed Mannich-type reaction by Suzuki et al. 
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Organocatalytic Mannich-type reactions have also been developed, where proline was 
used as the organocatalyst and aldehydes as the pronucleophiles.  Notz et al., utilizing a one pot, 
3-step procedure with in-situ imine formation, synthesized 23 different amino alcohols in 
moderate to good yields and enantioselectivity10 (Scheme 4). 
 
Scheme 4.  Synthesis of amino alcohols with proline in a 3 step procedure by Notz et al. 
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With the success of the 3 component Mannich reaction, it was clear that the imine can be 
generated in-situ with proline, successfully catalyzing the reaction as well as providing excellent 
enantioselectivity.  The products associated with the proline catalyzed reactions were all syn-
disubstituted β2,3-amino acid precursors.  Yang et al. and Vesely et al. also developed proline 
catalyzed Mannich-type reactions, but instead of generating the imine in-situ, they utilized boc 
protected imines and added them directly to the reaction.  Their products had limited substrate 
scope, where there were only aryl groups on the imine and a limited number of aliphatic groups, 
such as n-Bu, Me, and iPr on the aldehyde11,12 (Scheme 5).  The products of this reaction had 
excellent diastereoselectivity and enantioselectivity.    
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Scheme 5.  β-amino acid synthesis with proline as organocatalysts 
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The Mannich type reactions above (Schemes 2- 5) provide precedent in the synthesis of 
compounds with similar backbone and functionality as β-amino acids.  The products of the 
reactions also have diversity and good diastereoselectivity and enantioselectivity.  Based upon 
these reactions, it is evident that Mannich type reactions can be utilized in the synthesis of 
diverse and enantiomerically enriched β-amino acids required for peptidomimetics.         
 
1.3 SYNTHESIS OF Β-LACTAMS IN EFFORTS TOWARDS Β-AMINO ACIDS AND 
APPLICABILITY IN PEPTIDE SYNTHESIS 
 
Another strategy in the synthesis of β-amino acids is to use a β-lactam as a β-amino acid 
precursor because they have the same structural motifs.  With the same connectivity as β-amino 
acids, and being biologically active, themselves, the synthesis of β-lactams is an important area 
of β-amino acid synthesis and research.  One method of synthesizing β-lactams is through the 
synthesis of β-amino acids and their subsequent ring-closure.  Alternatively, β-lactams have been 
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previously ring-opened to access β-amino acids (Scheme 6).  The known interconversion 
between β-lactams and β-amino acids provides even more options for synthesizing β-amino acids 
as well as their use in peptidomimetics.      
Scheme 6.  Interconversion between β-lactams and β-amino acids 
R2 OH
ONH2
R1
HN
R2 R1
R2 OH
ONH2
R1
Oring-closure ring-opening
 
   
Although it is possible to synthesize β-lactams via ring closure of β-amino acids, there 
are a limited number of reactions that provide a diverse substrate scope of β-amino acids in good 
yields, diastereoselectivity and enantioselectivity.  The asymmetric synthesis of a number of β-
lactams has been accomplished by Hart et. al in 198613 and Lectka in 2002 (Scheme 7).14,15  
Hart’s example utilized a chiral auxiliary to obtain good enantioselectivity with a limited 
substrate scope including phenyl and cinnamyl groups on the imine portion and ethyl and 
isopropyl on the ketene portion.  Lectka’s example, albeit catalytic and providing excellent 
enantioselectivity, had limited substrate scope with only ester functionality present on the imine.   
 
Scheme 7.  Previous syntheses of enantioenriched β-lactams    
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With the ability to synthesize β-lactams shown by Hart and Lectka and the known 
interconversion between β-lactams and β-amino acids, ring-opening of β-lactams can be 
extended to β-peptide synthesis.  As seen in Scheme 8, the free amine of an amino acid acts as a 
nucleophile to ring-open the β-lactam, providing an alternative to the typical peptide coupling 
reactions.  In the use of β-lactams in the elongation of a peptide chain, typically an additive such 
as NaN3 or KCN is used (Scheme 8).16   
Scheme 8.  Ring-opening of β-lactam with an amino acid   
N
O
R1 R2
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H2N CO2R3
R
BocHN N
H
CO2R3
OR2
R1
R0.1 equiv NaN3
Et2O, 24 hr  
 
Although there have been a number of methods to directly synthesize β-amino acids as 
well as β-lactams that can lead to β-amino acids, current methods do not provide much diversity 
in functionality and stereochemistry.  There is still a great need for enantioselective synthesis of 
a large variety of β-amino acids with a diverse substrate scope.  
1.3.1 PREVIOUS METHODS OF β-PEPTIDE SYNTHESIS 
The majority of peptide synthesis is based on the formation of an amide bond via 
coupling of amines and carboxylic acids.  The coupling of amines and carboxylic acids typically 
consists of activation, deprotection and coupling (Scheme 9).  Due to the same terminal 
functionality, the same strategy used for α-amino acids can be also extended to β-amino acids.  
Other than the most common method of coupling carboxylic acids with amines, ring-opening of 
β-lactams as well as Wolff rearrangements have also been utilized.  Choosing the appropriate 
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coupling method depends on the availability of the β-amino acid, sensitivity of the substitution 
and protecting scheme.  
Scheme 9.  Traditional Strategy for peptide coupling 
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β-Peptide synthesis has been accomplished both in solution and with solid phase.  Chung 
et al. have synthesized a series of β-peptides in solution including a homochiral β-peptide (S) 
Boc-(β3HPro)n-OBn where n = 18 and heterochiral Boc-[(S)-β3HPro-(R)β3HPro]n-OBn where n 
= 3.  These β-peptides were synthesized via standard coupling reaction conditions with Boc as 
the nitrogen protecting group and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide 
hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) as the coupling reagents.17  β-Peptide 
synthesis has also been extended to solid phase where there are obvious advantages including 
ease of reagent removal and no isolation or purification of intermediates.  The typical method for 
solid phase peptide coupling involves the main-chain Fmoc/ side-chain t-butyl protecting scheme 
which is common in peptide synthesis.18 Other than the typical strategies for β-peptide synthesis, 
the Seebach group has also used the Wolff rearrangement conditions to perform peptide coupling 
(Scheme 10).19  
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Scheme 10.  Synthesis of trimer 10 via Wolff rearrangement and typical peptide coupling 
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Accessing new β-amino acids and providing a new strategy of β-peptide assembly would 
allow the synthesis of novel β-peptides.  One strategy for improving peptide synthesis is having 
preactivated amino acids, which would eliminate the activation step present in most standard 
peptide coupling sequences (Scheme 11). 
 
Scheme 11.  Strategy for peptide synthesis with preactivated amino acid 
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1.3.2 PAST RELATED RESEARCH WITHIN THE GROUP 
Acknowledging the need and utility of β-amino acids, research in the Nelson group has 
provided advances in the asymmetric synthesis of β-amino acid precursors with a variety of 
functionalization.  All of the developed methodologies were based upon Mannich reactions via 
catalytic asymmetric acyl halide-aldehyde cyclocondensation20 to form β-lactones (11) or acyl 
halide- imine cyclocondensation to form thiazinones (12) (Scheme 11).21  With the same strategy 
used for β-lactams, these heterocycles also have the same connectivity as β-amino acids and 
have proven to be useful building blocks for β-peptide synthesis upon ring-opening.   
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Scheme 12.  Strategy for use of heterocycles synthesized within the group using the acyl halide 
aldehyde or acyl halide imine cyclocondensation for β-amino acid synthesis   
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Peptide synthesis utilizing β-lactones has been accomplished with azide ring-opening of 
the lactone, reduction to the amine (13), followed by standard coupling of amine (13) and acid 
chloride (14), also generated from a ring opened lactone (Scheme 13). 
 
Scheme 13. Coupling of β-amino acids with β-lactones as starting material  
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 The thiazinone heterocycle, with syn-4,5 stereochemistry (15, Scheme 14) can also 
provide structurally diverse β2,3-amino acids, which can be utilized as building blocks in β-
peptide synthesis.  Ring-opening of these heterocycles has been previously shown to be 
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successful with both an amino acid, (S)-MeO-Val and with a hydride in good yields (Scheme 
13).  With the successful ring-opening of the thiazinone heterocycles and access to compounds 
that were very similar to β-amino acids, it was clear that there was great potential for their use in 
β-peptide synthesis. 
Scheme 14.  Strategy for synthesis and ring-opening of thiazinone heterocycles 
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The utility of these thiazinone compounds in β-peptide synthesis can be appreciated when 
realizing the advantages in this method.  These compounds can be synthesized asymmetrically 
with cinchona alkaloid organocatalysts in good yield and exceptional diastereoselectivity and 
enantioselectivity.  They can also provide a new method of peptide construction where the 
typical coupling can be avoided and peptide elongation is obtained via ring opening.  These 
enantioenriched highly substituted compounds are superb precursors of β-amino acids.   
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1.3.3 β-AMINO ACID SYNTHESIS VIA ASYMMETRIC KETENE, IMINE 
CYCLOADDITIONS 
Successful ring-opening and deprotection of the thiazinone heterocycles is critical for 
their utility in peptide synthesis.  Previous work in the group demonstrated that the thiazinones 
could be successfully ring-opened with an amino acid or hydride as the nucleophile (Scheme 13).  
With the ultimate goal of these compounds to be used in peptide synthesis, it was also necessary 
to have a deprotection strategy that supplies the primary amine for future peptide elongation and 
does not affect the peptide backbone.  A protecting group that allows selective, mild and fast 
deprotection was critical for success of this methodology.  We needed to avoid the most common 
amine protecting groups such as BOC, CBZ, FMOC and Ts, which require strong acids or 
hydrogenolysis for deprotection.  Although there are many alternatives for amine protecting 
groups, we are also limited by the origin of the protecting group in our substrate, which 
participates in the cycloaddition reaction.  With these limitations in mind and the success of 
dithiocarbamates in the cycloaddition reaction, we began to investigate strategies for the 
deprotection of different thiocarbamates.  There are multiple thiocarbamates to consider as 
potential protecting groups on the amine (Figure 5).  Assessing the use of thiocarbamates as an 
activating group in the cycloaddition and as a protection group for the amine was very important 
for the success in our peptide synthesis methodology.  
R2N OR
S
R2N SR
S
thionocarbamate
(O-thiocarbamate)
dithiocarbamate
R2N SR
O
S-thiocarbamate
 
Figure 5.  Nomenclature for thiocarbamate groups   
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There is no precedent for using a thiocarbamate group as an amine protecting groups in 
synthesis but these functional groups are observed in biological systems as protecting groups 
which are metabolized via oxidative processes.  In the oxidative metabolism of sulfides in nature, 
sulfides are oxidized to their corresponding sulfone, 17 (Scheme 15).  Dithiocarbamates, 18 are 
also known to be oxidized to sulfine compounds, 19 which can then be converted to stable 
disulfide compounds (20).  The metabolism of thionocarbamate groups where X =O also 
produced disulfide compounds upon oxidation.22  Oxidation of these compounds to their 
corresponding disulfide provides a more electrophilic center allowing for potential hydrolysis 
and access to the free amine.  Taking advantage of the known susceptibility of the thiocarbamate 
functional groups to oxidation, oxidative deprotection became our strategy.   
Scheme 15.  Proposed oxidation pathway of dithiocarbamates based on isolated intermediates22 
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With the known susceptibility of the thiocarbamate functionality towards oxidation, we 
anticipated that a mild oxidation agent would selectively oxidize the thiocarbamate over other 
functionality present on the substrate.  Upon selective oxidation of the thiocarbamate followed 
by hydrolysis, we could achieve orthogonal amine deprotection without affecting the peptide 
backbone.  For this purpose, we focused on a mild oxidation agent, Oxone.  No analogous 
 20 
reactions with Oxone in deprotection of a dithiocarbamate group were seen in literature; 
however, there are many examples of Oxone related oxidations of sulfur.23-26   
Our initial efforts toward deprotection were focused on the ring-opened products 
resulting from thiazinones with an inherent dithiocarbamate group.  At that time, we had only 
synthesized the thiazinones with the dithiocarbamate group.  All of our attempts to fully 
deprotect the dithiocarbamate group utilizing Oxone were unsuccessful; however we did 
observe the conversion of the dithiocarbamate group to thiocarbamic acid (Scheme 16). 
Scheme 16.  Unsuccessful deprotection of dithiocarbamate 
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 The conversion of the dithiocarbamate present in 21 to 22 with thiocarbamic acid 
functionality was unexpected and inconsistent with our initial proposed oxidation scheme.  We 
concluded that the thioether was being oxidized instead of the thiocarbonyl on the 
dithiocarbamate (Scheme 17).  
Scheme 17.  Proposed oxidation scheme for dithiocarbamate functionality 
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It was necessary to identify a protecting group that would both participate similarly to 
activate the cycloaddition reaction and be susceptible to the desired oxidative deprotection.  Due 
to the proposed cycloaddition mechanism where the sulfur of the thiocarbonyl functionality 
participated as a nucleophile in the cycloaddition, we investigated the thionocarbamate group, 
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(Figure 5).  The thionocarbamate group, similar to the dithiocarbamate, is electron withdrawing, 
activating the nitrogen towards deprotection and imine formation.  The nitrogen is also 
nucleophilic enough to participate in the Lewis acid coordination and nucleophilic addition.  As 
seen in Figure 6, the carbamate group on the amine has a significant role in the cycloaddition 
reaction.  The carbamate group contributes to the acidity of the amine, 23 coordinates with 
lithium in the transition state, 24 and nucleophilically adds into the activated acid, 25 resulting in 
the thiazinone cycloaddition products.  Although the characteristics of the thionocarbamate 
group makes it a good candidate for use in the cycloaddition, we also needed to consider its 
reactivity in the oxidative deprotection reaction.   
pTs
HN XR
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R2
N
S
RX
R2
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R1
Li
NR3
R3N
O
R1
N
R2
S
OEt
23 24 25  
Figure 6.  Participation of thiocarbamate functionality on the cycloaddition reaction   
 Our proposed route of oxidative deprotection (Scheme 17) was still plausible if we could 
alter the protecting group to favor oxidation at the thiocarbonyl instead of the thioether.  Based 
upon the analysis in Figure 6, the thionocarbamate has the correct functionality to participate in 
the cycloaddition, and lacked the thioether which was observed to oxidize instead of the desired 
thiocarbonyl when oxidative deprotection was attempted on the dithiocarbamate (Scheme 18).    
By changing the dithiocarbamate group on the α-amido sulfones to a thionocarbamate (23), we 
could accomplish this preference for thiocarbonyl oxidation and achieve the fully deprotected 
product.  A model substrate 26 was synthesized to test the success of deprotection of the S-
carbonyl thiocarbamate group (Scheme 18).   
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Scheme 18.  Model substrate deprotection 
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Conversion to the free amine was observed on this model substrate (Scheme 18). This is 
consistent with our proposed oxidation scheme where the substrate with the thiocarbonyl 26 was 
oxidized and subsequent hydrolysis resulted in the free amine 27.   
The only difference between the dithiocarbamate and the thionocarbamate functional 
groups was the presence of oxygen in the place of sulfur (Figure 5).  As mentioned previously 
(Scheme 15), oxidative metabolism of both of these compounds has been shown to result in 
stable disulfide compounds.  Upon hydrolysis of these compounds, the desired primary amines 
would be obtained.  The electronics of the thionocarbamate compared to the dithiocarbamate 
group would allow the imine 23, where X=O to successfully undergo the cycloaddition and 
provide the necessary functionality for oxidative deprotection, making it a superior protecting 
group for our peptide synthesis methodology. 
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Scheme 19.  β- Amino acid synthesis via thiazinone precursor 
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1.4 SYNTHESIS OF THIOCARBAMATE PROTECTED SULFONES AND THEIR 
USE IN THE CYCLOADDITION 
Acknowledging that the thionocarbamate is a good candidate for both the cycloaddition 
and oxidative deprotection, we began the synthesis of a variety of thiazinones containing the 
thionocarbamate group on the amine.  A series of thionocarbamate-derived a-amido sulfones 
were prepared and their performance in the cycloaddition was examined.  Synthesis of the 
sulfones was easily accomplished where each of the desired aldehydes was either commercially 
available or could be synthesized in a short number of steps in high yields.  With the ultimate 
goal to utilize these compounds in peptide synthesis, we designed our substrate scope to mimic 
naturally occurring amino acid side chains (Figure 7).   
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Figure 7.  Synthesis of β-amino acid based on side chains of α-amino acids 
     
From a mechanistic perspective, the thionocarbamate group can participate in the 
cycloaddition reaction similar to the dithiocarbamate group (Figure 8).  In practice, however, 
when running the cycloaddition reaction with the thionocarbamate group on the sulfone, a much 
less productive cycloaddition was observed with minimal product formation.  Further 
optimization for this reaction with the thionocarbamate was necessary.  The difference in 
reactivity between the thionocarbamate and the dithiocarbamate was attributed to the difference 
in electronics of these functional groups and their coordination with the Lewis acid which is 
believed to coordinate with the dithiocarbamate.  With a few modifications of the cycloaddition 
reaction, which included changing the Lewis acid from LiClO4 to LiI (Figure 9) and adding the 
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acyl chloride portion-wise, we were able to obtain the desired heterocycles in good yield with the 
thionocarbamate functionality.   
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Figure 8.  Synthesis of sulfone starting material   
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Figure 9.  Optimal Lewis Acid for cycloaddition reactions 
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Figure 10.  Cycloaddition Results with Thionocarbamate Protection and Amino Acid based 
Substitution 
 
   
 With the optimized reaction conditions, different substituents designed to mimic amino 
acids were subjected to the cycloaddition reaction involving the thionocarbamate.  From these 
series of cycloaddition reactions, it was clear that there were several differences between the 
thionocarbamate cycloaddition reaction and the dithiocarbamate cycloaddition reaction.  The 
most significant difference between the cycloadditions was the formation of both the thiazinone 
and β-lactam (Figure 10).  Previously, in the dithiocarbamate reaction, only the thiazinone was 
observed (Figure 11).   In the thionocarbamate cycloadditions, thiazinone (30) and β-lactam (31) 
were both observed and in different ratios depending on the sulfone substrate (Figure 10).  In all 
cases, with the exception of the indole substituent (Figure 10, Entry F), the thiazinone (30F) was 
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the major product formed.  The greatest selectivity in terms of preference for thiazinone 
formation was with the isovaleryl functionality on the sulfone (Figure 10, Entry A), where the 
ratio of isolated thiazinone (30A) to β-lactam (31A) was 8:1.  The two different cycloaddition 
products from the reaction involving the thiocarbamate group also had different relative 
stereochemistry, where the side groups on the thiazinone were syn and on the β-lactam, they 
were anti.  The product formation and the stereochemistry of these products gave us insight into 
how the mechanism of the cycloaddition reaction with the thionocarbamate functionality was 
different from the reaction with the dithiocarbamate functionality.   
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Figure 11.  Difference in product formation between the dithiocarbamate and thionocarbamate 
substrates in the cycloaddition 
The difference in product formation upon modification of the carbamate can be 
rationalized by looking at the proposed mechanism of the cycloaddition in Scheme 19.  Both the 
sulfur and the nitrogen of the thionocarbamate can act as nucleophiles in the cycloaddition.  The 
thiazinone is formed when sulfur acts as the nucleophile and the β-lactam results from addition 
of the nitrogen into the activated acid.  Additionally, it was observed that the thiazinones and β-
lactams exhibit different relative stereochemistry about the newly formed bond, whereas the 
enantioselectivity was consistent in both the thiazinone and β-lactam and R1 was always R.  The 
difference in relative stereochemistry for these two products indicated that the mechanism 
differed not only by which nucleophile added into the activated acid, but also by the transition 
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state during addition of the enol into the imine.  The anti- relative stereochemistry of the β-
lactam suggested that the ketene added into the opposite face of the imine component TS2.  
Following the enol addition, either the sulfur or the nitrogen of the carbamate can add into the 
activated acid and produce the thiazinone or β-lactam, respectively (Scheme 19).  Based on the 
observation that the syn- products were only seen as the thiazinone and the anti- products were 
only seen as β-lactams, it was evident that the syn- organization enforced the conformation for 
the sulfur addition and the anti- organization enforced the conformation for nitrogen addition.    
 
Scheme 20.  Proposed mechanism for rationalizing synthesis of thiazinone and β-lactam 
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As mentioned previously, the ratio of thiazinone and β-lactam differed for each substrate.  
The ratio was strongly influenced by the R2 group on the substrate.  An analysis of the proposed 
cyclocondensation transition states reveals one possible explanation for the substrate-dependent 
chemoselectivity.  The strength of coordination to the Lewis acid in the transition state would 
differ between the dithiocarbamate and the thionocarbamate.  The participation of the Lewis acid 
in the cycloaddition was demonstrated to be necessary when in order to achieve the 
cycloaddition reaction with the thionocarbamate sulfone instead of the dithiocarbamate, we 
needed to change the Lewis acid from LiClO4 to LiI.  Due to the electronic difference between 
the dithiocarbamate and the thionocarbamate, LiI, a stronger Lewis acid than LiClO4 was needed 
to aid in coordination with the carbamate in the transition state.    There would be a tighter 
coordination with the dithiocarbamate than the thionocarbamate and therefore greater energy 
difference between the two proposed transition states, TS1 and TS2, providing a definite 
preference for syn stereochemistry leading to the thiazinone.  This preference was reflected in the 
isolated thiazinones having exclusively syn- stereochemistry.    
The proposed transition state, leading to the syn-stereochemistry of the thiazinone is a 
chair-like, closed transition state TS1 where the lithium Lewis acid can coordinate to the oxygen 
of the enol and the sulfur of the thionocarbamate.  The formation of the thiazinone, 30 containing 
the dithiocarbamate group participates in the same transition in the formation of the thiazinone 
with syn-stereochemistry.  The transition state leading to the anti-stereochemistry TS2 found on 
the β-lactam, 31 suggests that the enol would add to the other face of the imine.  When the 
substituents on the imine were more remote, such as in entries B-E (Figure 10) where there were 
at least 2 methylenes between the reactive center and the bulky functionality, it was observed 
that approximately 50% of thiazinone and 30% of β-lactam was isolated.  In the case of entry A 
 30 
containing an isovaleryl group, 79% isolated yield of thiazinone with syn-stereochemistry and 
10% isolated yield of β-lactam with anti-stereochemistry was obtained.  There was a clear 
preference for transition state TS1, leading to the syn-diastereomer and thiazinone formation.  
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Figure 12.  Syn- vs Anti- orientation in transition state for different side chains and 
thiocarbamates 
   
Out of the substituents utilized in the cycloaddition reaction, the indole substituent (Table 
1, Entry F), was the only example where there was more isolated β-lactam than thiazinone.  
Unfortunately, the combined yield of both of the cycloaddition with the indole substrate was 
only 39%, indicating the sensitivity of the substrate which complicated the analysis of the 
preferred transition state based on isolated product distribution.  The combined yield of 39% was 
obtained after further modification of the cycloaddition reaction for this sensitive indole 
substrate.  Under the initial cycloaddition reaction conditions that were used for the other 
substrates, the combined isolated yield when using the indole sulfone, 29F, was only 30% which 
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consisted of a 3:1 ratio of enamine to thiazinone (Figure 10, Entry F).  The formation of a large 
amount of enamine was attributed to the high acidity of the α-proton on the imine.  The indole, in 
conjugation with the anion, stabilizes the intermediate leading to the enamine (Scheme 21).  The 
indole substrate is very reactive to the basic conditions which led to unproductive side products 
such as enamine formation and decomposition.  The production of a large amount of enamine 
when the sulfone contained the indole functionality was unique in the cycloaddition reactions, 
where most of the sulfones contained alkyl groups or other remote functionalities did not lead to 
a significant amount of enamine formation.  Because the enamine formation prevented 
productive cycloaddition, this sensitive functionality required a modified procedure.  
 
Scheme 21.  Enamine formation of indole substituent 
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1.5 MODIFICATION OF THE CYCLOADDITION REACTION DUE TO 
SENSITIVITY OF INDOLE CONTAINING SUBSTITUENT 
In efforts to improve the cycloaddition reaction with the indole substrate and to avoid 
enamine formation, it was necessary to facilitate the reaction with the imine intermediate and 
prevent unproductive tautomerization leading to enamine.  Any additional time that the 
unreacted imine is present in the reaction mixture is a potential opportunity for tautomerization 
or other unwanted side reactions leading to decomposition to occur.  From the proposed 
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mechanism (Scheme 22), the cinchona alkaloid catalyst plays a critical role in the desired 
reaction of the imine.  It is believed that the cinchona alkaloid adds into the ketene to form an 
enolate, 34 which can then add into the imine, 37.  The increase of the cinchona alkaloid catalyst 
would result in more of the reactive intermediate 34, facilitating the desired reaction with the 
imine and interrupting the tautomerization process.  When the amount of cinchona alkaloid 
catalyst was increased to 100%, as seen in Table 2, the isolated yield of cycloaddition products 
increased from 8% to 18% and the amount of isolated enamine decreased from 22% to 18%.  
Although a slight improvement in yield was observed with the increase of cinchona alkaloid 
catalyst, further optimization was still required to improve the 34% combined isolated yield.   
 
Scheme 22.  Mechanism of Indole substrate in the cycloaddition reaction 
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The cycloaddition reaction involving the indole sulfone required more optimization when 
considering that the total amount of isolated compounds including the enamine and both 
cycloaddition products never exceeded 34%.  Based on the isolated products from the reaction, 
approximately 60% of the sulfone starting material resulted in unidentified decomposition 
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products.  To decrease the amount of time that the sensitive unreacted imine was present in the 
reaction, the sulfone, 29F was added portion-wise to the solution.  Combined isolated yield of 
enamine and cycloaddition products rose from 34% to 81%.  Although a large amount (18%) of 
enamine was still isolated, there was a marked improvement in the reaction where 20% of 
thiazinone and 43% of β-lactam was obtained as productive cycloaddition products.  The 
portion-wise addition of the sulfone dramatically increased the amount of desired products, 30F 
and 31F.  There was not a large amount of unidentified sulfone decomposition products as seen 
in the previous reactions.  The optimized addition procedure for the cycloaddition reaction with 
the indole substrates (Figure 13), can be extended to the use of other sensitive substrates that are 
found to quickly tautomerize in the cycloaddition reaction conditions.  Although the optimized 
method was procedurally intensive, the portion-wise addition of the sensitive sulfone starting 
material dramatically increased the success of the reaction. 
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Figure 13.  Optimized procedure for compounds with fast tautomerization   
 
For the cycloaddition reactions involving a sulfone that quickly tautomerizes to an 
unproductive enamine compound, an optimized procedure was developed where the amount of 
cinchona alkaloid catalyst was increased and the sensitive sulfone was added portion-wise.  This 
new procedure was developed with the indole substrate and the most dramatic increase in yield 
occurred when the sulfone was added in multiple small portions.  With the significant amount of 
isolated enamine (18%) persisting throughout these improvements, another method of modifying 
the indole substrate to decrease enamine formation was examined.  Modification of the 
protecting group on the indole provides an opportunity to attenuate the acidity of the α-proton.  
Modification of the protecting group on the nitrogen affects the electron density of the nitrogen 
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therefore also affecting the contribution of the nitrogen to the conjugated system.  A small screen 
was run with different protecting groups on the indole nitrogen.  Electron rich protecting groups 
such as benzyl and allyl performed better in the reaction and the isolated yield of the thiazinone 
and β-lactam was 50% or greater.  With electron withdrawing groups on the indole nitrogen, 
such as tosyl, only enamine was isolated in 22% yield and no cycloaddition products were 
observed.  The CBZ protecting group on the nitrogen only resulted in β-lactam in 22% yield 
(Table 1).   
 
Table 1.  Cycloaddition results with the indole substituent with different protecting groups and 
reaction conditions 
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CBZ 21% - 22% 43%
Ts 24% - - 24%
allyl 16% 17% 29% 62%
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C
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Overall, electron- donating groups on the indole nitrogen were found to give more 
amounts of cycloaddition products than electron- withdrawing counterparts.  The difference in 
reactivity we observed with the different protecting groups on the amine correlated well with the 
predicted sensitivity of the compound due the acidity of the α-proton.  The electron withdrawing 
groups on the nitrogen of the indole would make the α-proton more acidic and facilitate 
deprotonation and tautomerization to the enamine.  Electron donating groups would provide 
more electron density to the α-proton and destabilize the anion leading to enamine formation.  
The electron rich benzyl protecting group on the nitrogen of the indole was found to be superior 
in the cycloaddition reaction with the greatest combined isolated yield of 81%.  In this 
cycloaddition reaction, tautomerization to enamine only contributed 18% of sulfone conversion.  
The electron rich benzyl protection group succeeded in decreasing the sensitivity of the indole 
sulfone.  The final optimized conditions for the indole sulfone involved 100% cinchona alkaloid, 
portion- wise addition of sulfone and a benzyl protecting group on the nitrogen of the indole. 
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2.0  PEPTIDE SYNTHESIS UTILIZING THIAZINONE AND ΒETA-LACTAMS 
Diversity is a key component of peptide synthesis.  The diversity found in peptides 
originates from the structure and stereochemistry found in the amino acids that construct the 
peptides.  With increased structural and stereochemical diversity of amino acids, it is possible to 
synthesize peptides with desired characteristics.  Similar to most organic compounds, desirable 
characteristics for peptides include solubility, stability and diversity of functionalization.  
Although α-peptides have the same backbones as β-peptides, their conformational preference and 
the secondary structure they adopt is significantly different.  This conformational difference has 
major implications on solubility and biological activity of peptides.  The ability to control not 
only the substitution pattern, but also the relative and absolute stereochemistry of the β-peptide 
building blocks would provide the diversity that is critical for the synthesis of unnatural peptides 
with the desired characteristics. 
Scheme 23.  Ring-opening of heterocycles in the formation of β-amino acids   
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In our synthesis of β-amino acid precursors, two different heterocycles, the thiazinone 
and β-lactam, were obtained from the cyclocondensation reaction.  These compounds have 
different relative stereochemistry and are also easily separable via routine column 
chromatography.  Upon ring opening and deprotection, the thiazinones provide 2,3-syn β-amino 
acid while the β-lactam affords 2,3-anti β-amino acids (Scheme 23) which can both be 
incorporated into peptides.  The ability to synthesize and ring open a variety of thiazinones and 
β-lactams and achieve their respective β-amino acids would significantly add to the diversity 
available in synthetic peptides and peptidomimetics.      
2.1 METHOD DEVELOPMENT OF RING-OPENING REACTIONS 
Dithiocarbamate thiazinones have been successfully ring opened via addition into the 
thioester carbonyl functionality on the heterocycle by both amino acid and hydride nucleophiles 
(Scheme 14).27  The addition into the thiazinone heterocycle is very favorable due to the 
increased electrophilic nature of the thioester compared to standard esters or ketones.  The 
increased electrophilic nature of the thioester can be attributed to the relatively poor orbital 
overlap of the large sulfur to carbon compared to the better matched overlap between oxygen and 
carbon of the analogous ester28.  Accordingly, the thiazinones emerge from the 
cyclocondensation reactions preactivated for ring-opening with a variety of nucleophiles.  
Although β-lactams do not contain the electrophilic thioester functionality, they are also 
inherently activated towards nucleophilic ring opening at their amide bond linkage due to the 
ring strain that is released upon ring opening.  With both of our synthesized amino acid building 
blocks preactivated towards ring opening and the importance of ring opening in our ultimate goal 
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of peptide synthesis, we anticipated that both of the products of our cycloaddition reaction would 
be exceptional precursors for β-amino acid synthesis. 
To further investigate the electrophilic properties of the thiazinone and β-lactam 
compounds towards nucleophilic ring opening, we examined the success of the ring opening 
reaction with a variety of nucleophiles.  Secondary and primary amines were found to effect ring 
opening of the thiazinones in exceptional yields of 88-98%.  Additionally, methanol was also 
found to be an effective nucleophile and provided the ring opened products in 90-96% yield.  
From these investigations, it was clear that we were not limited in our use of nucleophile and 
both the thiazinone and β-lactam would perform well in a variety of ring opening reactions 
which are necessary in the initial ring opening and elongation of the peptide.      
Another important quality of our compounds and their use in peptide synthesis is their 
ability to be deprotected.  As discussed previously, the dithiocarbamate group from the ring 
opened dithiocarbamate thiazinones was not successfully oxidatively deprotected.  With the 
modification of the dithiocarbamate group to a thionocarbamate group, the oxidative 
deprotection was successful using oxone as a mild oxidant.  When the thionocarbamate was 
treated with Oxone, the primary amine, 27, was obtained in near quantitative yields, regardless of 
the functionalization of the thionocarbamate. With both the ring opening and deprotection 
reactions developed, these reactions could be utilized in an iterative fashion towards the 
synthesis of β2,3-peptides. (Scheme 24).     
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Scheme 24.  Proposed iterative β-peptide synthesis with thiazinones as β-amino acid precursors 
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 Like most organic reactions, it was found that the solubility of the substrate had a major 
effect on the success of both the ring opening and deprotection reactions.  To optimize the 
solubility of the substrate without affecting the stereochemistry or substitution on the amino acid 
backbone, the functionality on the C-terminus was modified.  The functionality of the C-
terminus originates from the nucleophile which is used to ring open the first thiazionone as seen 
above in Scheme 23.  Methanol was used as the first nucleophile and was maintained throughout 
the synthesis on the C-terminus as a methylester.   In changing the initial nucleophile, we could 
modify the solubility of the peptide while not affecting the stereochemistry or substitution on the 
amino acid backbone.  The dimers in Scheme 25 were synthesized via the methodology seen in 
Scheme 24 to investigate the effect of the C-termini functionality on the solubility of the 
substrate.  Due to the observation that insolubility problems arose at the dimer level, the success 
of deprotection of the dimers was compared (Scheme 25).  As seen in the results of the 
deprotection reaction of each of the synthesized dimers, there was a major difference in reaction 
success depending on the C-termini and solubility of the substrate (Scheme 25).   
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Scheme 25.  Solubility effects on deprotection reaction success 
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It was observed that the success of the reaction was directly related to the solubility of the 
substrate.  When a benzylamide was present on the C-terminus of the dimer, the starting 
material, 38 was insoluble in the aqueous THF solution.  The insolubility resulted in a lack of 
reactivity.  When the starting material 38 was subjected to the deprotection conditions, no 
reaction was observed.  Due to previously successful deprotection reactions on compounds with 
very similar functionality, the lack of reactivity was assigned to the insolubility of the starting 
material.  Insolubility of the benzyl amide, 38 was not surprising due to the tendency of 
benzylamides to aggregate and form highly organized crystalline structures.29  Anticipating that 
an N,N-dialkyl amide would exhibit enhanced solubility in common organic solvents compared 
to the benzyl amide, a dibutyl amine was used as the initial ring opening nucleophile in the 
synthesis of dimer 40.  Dimer 40, with the dibutyl amide on the C-terminus was then tested in the 
deprotection reaction.   As expected, the more soluble dimer 40 performed much better in the 
deprotection reaction, where 78% yield of desired deprotected dimer 41 was obtained compared 
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to 0% of deprotected dimer 39.  Increased solubility of 40 was not only observed through the 
much improved yield of the deprotection reaction but also could be seen visually in the reaction 
solution, where most of the starting material was soluble in the aqueous THF solution.  Due to 
the heterogeneity of the reaction solution which contained the insoluble reagent, Oxone, it was 
difficult to visually determine the solubility of the starting material.  Although the dimer with the 
dibutyl amide C-terminus performed much better in the reaction than the dimer with the benzyl 
amide on the C-terminus, we had previously found the deprotection reaction to be near 
quantitative in reactions where the starting material was completely soluble.  
Fixing the solubility issue and obtaining better yields in the ring opening and 
deprotection reactions was critical for the success of synthesizing peptides past the dimer stage.  
In the previously discussed dimers 38 and 40, the solubility issues originated from the nature of 
the rigid polyamide backbones and potential hydrogen bonding between molecules.  Although 
these characteristics are present in all peptides, we synthesized dimer 42 where the methyl ester 
functionality on the C-terminus would avoid the potential hydrogen bonding of an amide bond.    
When subjected to the same deprotection condition on the dimer with the methyl ester on the C-
terminus, the deprotected product was obtained in 97% yield.  Dimer 42 was much more soluble 
that the previous dimers and an overall better candidate for peptide synthesis.  Changing the 
nucleophile to modify the functionality of the terminus greatly affected the solubility of the 
peptides and their subsequent success in future reactions.  Peptides possessing methyl ester 
termini were found to exhibit superior solubility in the reaction conditions and performed better 
in the reactions.  The methyl ester at the C-terminus is also easily saponified to the carboxylic 
acid which is the functionality typically used in traditional peptide synthesis.  With the 
conversion of the C-terminal methyl ester to a carboxylic acid, our peptides can be incorporated 
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into traditional peptide synthesis schemes, particularly into peptidomimetics when it is desired to 
install a β-amino acid into an α-peptide.  For these reasons it was determined that the methyl 
ester was superior to the amide for use in our reactions and for application into traditional 
peptide synthesis.        
With the methyl ester determined as the preferred functionality on the C-terminus, our 
methodology based upon reiterative ring opening and deprotection reactions (Scheme 26) was 
utilized to accomplish highly complex and functionalized β-peptides.  To show the capability of 
this methodology towards the synthesis of diverse β-peptides, we synthesized a variety of β-
peptides consisting of either 3 or 4 β-amino acids with varying backbone substitution and 
stereochemistry.  Using our optimized ring opening and deprotection procedures (Schemes 26 & 
27), the peptides, (49, 51 & 53) were efficiently synthesized.  In the synthesis of 49, yields of the 
deprotection reaction using Oxone in an aqueous THF solution were good and within the range 
of 73-97%, with the exception of the deprotection of the tetramer which was a low 57%.  The 
ring opening reactions in the synthesis of 51, using the same methodology as the synthesis of 49, 
were consistently high yielding where the yields ranged from 90-93% except one low yield of 
53% yield in the ring opening to synthesize the trimer.  The low yield of this ring opening is 
attributed to the insolubility of the protected trimer of this series and the difficulty in its isolation 
and purification.    
Although both of our synthesized thiazinones and β-lactams can be used as β-amino acid 
precursors, only thiazinones were utilized in the synthesis of peptides (49,51&53).  The 
substitution on the peptide backbone is not affected by the choice β-amino acid precursor as they 
both have the same substitution, but the stereochemistry between them does differ.  The 
thiazinone has syn-stereochemistry, resulting in the syn-β-amino acid stereochemistry seen on the 
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peptides (49,51&53).  If β-lactams, with anti-stereochemistry were used, they would result in 
anti β-amino acid stereochemistry upon ring opening.   
 
Scheme 26.  Peptides synthesized in solution (yields in parentheses are after ring-opening and 
deprotection steps) 
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Peptide 53 was only extended to 3 β-amino acids due to the sensitivity of the indole 
substituent when subjected to the oxidative deprotection conditions (Scheme 27).  Upon 
exposure of the indole containing peptide to the oxidative deprotection reaction conditions, many 
undesired side products were observed in the crude reaction mixture including many of which 
were debenzylated.  It is suspected that the electron-rich nitrogen of the indole was susceptible to 
undesired oxidation.  Other substrates which did not contain the indole did not exhibit this 
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sensitivity.  The inability to utilize the oxidative deprotection on peptide 53, which contained the 
indole substituent prevented any further ring openings with this peptide and thus was not 
extended past the trimer.     
 
Scheme 27.  Synthesis of peptide with indole functionality   
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The presence of the methyl ester instead of the amide bond at the C-terminus of the 
peptide was advantageous not only for solubility reasons as discussed previously, but also for 
purposes of incorporating our amino acids and peptides into traditional peptides.  The methyl 
ester can be easily converted into a carboxylic acid via saponification.  Traditional peptide 
coupling reactions involve the reaction of an amine and a carboxylic acid and with the 
conversion of the methyl ester to a carboxylic acid, our peptides can also be utilized in this 
traditional peptide coupling manner.  Compatibility with traditional peptide synthesis provides an 
easier way to incorporate these compounds seamlessly in a traditional peptide synthesis scheme 
as well as allowing for convergent synthesis of peptides instead of growing the peptide chain 
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sequentially.  The convergent synthesis of a tetramer was performed where two dimers were 
synthesized via our ring-opening and deprotection scheme followed by saponification of one of 
the methyl ester 54 to obtain acid 55 in 96% yield, and traditional coupling with deprotected 
dimer, 46 to obtain tetramer 56 in 65% yield.   
 
Scheme 28.  Utility of synthesis of methyl ester β-peptides in standard peptide coupling reactions 
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As demonstrated by the various peptides synthesized, the developed ring opening and 
deprotection reactions were very amenable to peptide synthesis in solution.  We accomplished 
what we had initially intended which was to develop an efficient method for the de novo 
synthesis of highly functionalized β-peptides with high enantiopurity.  As previously discussed, 
the methyl ester termini can be converted to a carboxylic acid which can then be used in 
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traditional peptide coupling between amino acids as demonstrated in Scheme 28.  This 
methodology is potentially most useful in the context of peptidomimetics where incorporation of 
a β-amino acid with a peptide is desired.  In our synthesis of peptides (49,51&53), the only 
problems we encountered were due to insolubility and substrate sensitivity which arose when the 
β-peptide was extended to four amino acids and contained other highly oxidizable 
functionalities.  The design of our methodology to utilize our building blocks to be easily ring-
opened and deprotected has proven to be very successful and allowed for the synthesis of 
multiple β-peptides that can also be easily utilized in the context of typical peptide synthesis and 
peptidomimetics.  
2.2 SOLID SUPPORT SYNTHESIS OF PEPTIDES 
Due to the iterative design of peptide synthesis which is conducive to automation, as well 
as the difficulty in purifying peptides, it is not surprising that most peptide synthesis is done on 
solid support.  There are many advantages to solid support synthesis such as ease of operation 
and purification.  Solid support synthesis provides the ability to remove all reagents and by-
products in solution by rinsing of the solid support beads.  Furthermore, there is no isolation and 
purification of intermediate compounds needed.  Although our β-amino acid precursors are 
unique and require different coupling and deprotection reaction conditions relative to traditional 
peptide coupling between amino acids with carboxylic acid and primary amine termini, the 
similar iterative design makes our method very amenable to solid support peptide synthesis.  
Performing our ring-opening based β-peptide synthesis on solid support was an obvious 
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extension for our methodology where it would make our reactions significantly more efficient 
and convenient.   
 
Scheme 29.  β-Peptide synthesis on solid support 
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The general scheme for peptide synthesis on solid support is identical to the scheme for 
solution phase peptide synthesis.  In the general scheme, amide peptide bonds are formed via the 
coupling of amines with activated acids.  Although the scheme is identical, modifying certain 
reaction conditions for the solid support peptide synthesis is necessary.  For example, the solvent 
of the reaction must be changed to accommodate for the solvation and swelling of the solid 
support bead, allowing proper mixing and reacting.  The solid support that was used in our solid 
support synthesis was the NovaPEG rink resin (Figure 14) which has relatively uniform swelling 
properties across a range of solvents including very polar solvents such as water, DMF, DMSO 
and acetonitrile with swelling of  11, 9, 8 and 6 (mL/g) respectively30.  
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Figure 14.  NovaPEG rink resin used in solid support   
Acetonitrile, which is the solvent utilized in the solution phase ring opening reactions has 
a much smaller swelling capability than DMF, where acetonitrile is 6 mL/g and DMF is 9 mL/g.  
For this reason, DMF was used as the solvent in the solid support ring opening reactions.  Our 
deprotection reactions in solution were run in a solution of aqueous THF.  In the analogous solid 
support reaction, we utilized dioxane instead due to the higher boiling point of dioxane 
considering the possibility that heating of the reaction may be desired.  Matching the desired 
polarity for the success of the reaction as well as the necessary swelling of the solid support 
bead, we determined the appropriate solvents to be DMF for the ring opening reaction and 
aqueous dioxane in the deprotection reaction.   
Different from typical peptide coupling reactions found in most solid support peptide 
synthesis, we needed to develop reaction conditions to accommodate our methodology of ring 
opening and deprotection reactions on solid support.  Solid support reaction conditions that were 
conducive to loading the first residue on the bead required the use of a resin with a free amine.  
Utilizing the NovaPEG rink resin, we began to investigate conditions in which this solid support 
could add into our thiazinone or β-lactam precursors.  It is also critical in solid support reactions 
that there is 100% reaction completion before the next step.  Inefficient solid support coupling 
reactions lead to a variety of peptide fragments which would be difficult to separate from the 
desired peptide where all of the amino acids had added successfully.  Accordingly, it was 
essential to identify optimal reaction conditions that provided complete reaction.   
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We began our solid support synthesis with similar reaction conditions used in solution, 
where the reaction was run at room temperature for 17 hours in a DMF solution.  After cleavage 
of the monomer off of the bead, only 56% of the cleaved monomer was isolated (Table 2, Entry 
A).  In order to improve the yield and reaction efficiency, microwave irradiation, which has been 
previously utilized in solid support β-peptide synthesis1, was also explored.  Based upon typical 
peptide coupling between primary amines and activated carboxylic acids, we utilized standard 
microwave conditions that were previously successful for solid-phase peptide synthesis on β-
peptides with our thiazinones.31  Accordingly, the reaction conditions involved the addition of 
the solid support, thiazinone, DMAP and DMF, irradiating the solution up to 40ºC and holding at 
that temperature for 4 minutes (Table 2, Entry A).  Unfortunately, we obtained only a 37% 
isolated yield of desired product from this method after cleaving the monomer from the bead.  In 
order to cleave the product off the solid support, a 95% TFA solution was added.  After 
appropriate mixing, the solution was filtered off and concentrated to afford the final product.  
Purity of the isolated product off of the resin was verified by NMR  Even with higher 
temperatures and longer times, the maximum yield of cleaved product was only 46% (Table 2, 
entries C & D).  The yields obtained from these experiments, where the highest yield of isolated 
product was found to be 56%, are unacceptable for solid support peptide synthesis, especially 
when considering the need for complete reaction of the free amine.  It was necessary to 
determine whether the low yield was due to the coupling reaction or the process of cleaving the 
product from the bead.     
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Table 2.  Solid Support Coupling using Microwave Conditions 
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In order to study the success of both the ring opening and cleavage reactions in the solid 
support peptide synthesis, we needed to develop a new method to analyze these reactions.  
Although yields are frequently useful for determining conversion and success of reactions, in 
solid support reactions isolated yields represent multiple steps including cleaving the final 
product from the solid support.  It was necessary to determine the success of the ring opening 
independent of the cleavage reaction.  For more evidence of the success of the ring opening 
reaction, TLC’s were taken after each reaction.  The β-amino acid precursors, the thiazinone and 
β-lactam are both UV active and the loss of these compounds upon reaction with the amine could 
be monitored via TLC.  The product, which would consist of the protected amino acid on the 
bead would not be soluble and would not be observed on the TLC.  This difference in UV 
activity of the starting material and product would provide a method to monitor and analyze the 
success of the ring opening reaction.  Upon complete reaction there would be no remaining UV 
active starting material.  Interestingly, in the reaction that was run at room temperature where 
56% of the cleaved product was obtained, reaction completion was confirmed when no UV 
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active starting material was observed by TLC.  If this reaction was complete as the TLC 
suggested, the cleavage reaction should provide near quantitative yield.  It was evident that the 
cleavage reaction needed to be optimized, where a reaction that was observed to be complete by 
TLC only provided a 56% yield of cleaved isolated product.  
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Figure 15.  Analysis of Reaction Through Monitoring loss of Starting Material on TLC 
Other than the qualitative method of monitoring the reaction progress via TLC, it was 
necessary to also quantitatively analyze the success of the reaction.  We selected gas 
chromatography for this purpose since it was determined to be the most appropriate method to 
observe the progress of this reaction via loss of starting material.  To the acetonitrile solution 
with solid support was added naphthalene, DMAP and thiazinone (Scheme 30).  At specified 
time points, a very small aliquot of the solution was removed from the sample and analyzed via 
GC using naphthalene as an internal standard.  To determine the consumption of thiazinone, the 
ratio of naphthalene to thiazinone was calculated.  It was determined through these experiments 
that 80% of the reaction was completed in the first 5 hours followed by a slower reaction  where 
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by 15 hours, the reaction had completed.  It was evident that the reaction was occurring 
immediately upon addition of the substrate and initially proceeded at a fast rate, but the extended 
time was necessary to ensure complete reaction.  After optimization of the ring-opening reaction 
in the solid support peptide synthesis which involved lengthier reaction time at room temperature 
and excess thiazinone (5 equiv.), we achieved the monomer in 81% yield after cleaving (Scheme 
31).   
Scheme 30.  General Scheme for GC Experiment 
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Scheme 31.  Cleavage of product off of solid support with TFA   
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At this point, we have achieved successful ring opening and cleavage on the solid 
support.  However, to elongate the chain, it was necessary to also accomplish deprotection on the 
solid support in order to allow for subsequent coupling reactions.    We needed to verify that our 
thionocarbamate deprotection conditions were compatible with solid phase synthesis.  
Investigating the deprotection reaction was more difficult than the ring opening.  As it was 
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difficult to monitor the deprotection reaction using conventional methods (TLC, GC, etc.) we 
adopted a protocol where the deprotected material was used directly without quantification.  We 
chose to run the deprotection reactions and instead of cleaving to see the amount of deprotection, 
continue with the coupling reaction.  Due the high efficiency we observed in the solution phase, 
we believed the deprotection would work similarly well in the solid support reactions.  Indeed, 
our original reaction conditions did prove effective requiring only a change of solvent to achieve 
maximum yields. Thus, a mixture of dioxane and water was used.    The preceding investigations 
led to the following optimized procedure that was used to make 57, 58 & 59 (Figure 16).  
Although we were unable to isolate the deprotected monomer after cleavage, it was clear from 
the high yields obtained from the solid support synthesis of the trimers (96% and 87%) and 
tetramer (53%), the deprotection reactions were successful (Figure 16). The yields of trimers 
were much greater than the tetramers.  This is believed to be caused by the increased insolubility 
observed as the length of the peptide increased.  Consistent with the efficiency provided in the 
use of solid support instead of solution phase, we observed much higher yield (53%) in the solid 
support synthesis of peptide 59, whereas only 23% of very similar peptide 56 was obtained from 
synthesis in solution (Figure 17).    
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Figure 16.  Peptides synthesized on Solid Support 
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Figure 17.  Comparison of yields for solution vs. solid support   
  
With the increased yield observed and operational efficiency of our methodology on solid 
support, it was important for us to be able to incorporate our synthesized peptides into traditional 
peptide synthesis to allow for use in peptidomimetics.  As seen in Figure 16, the products from 
the solid support which result from the cleavage of the compounds from the rink amide resin 
resulted in primary amide functionality.  Unable to use these primary amides directly in peptide 
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synthesis, a method was desired to convert a primary amide into a carboxylic acid, but would not 
affect the thionocarbamate on the amino terminus of the molecule.  Sodium nitrate was found to 
do just that, where 62% of the desired carboxylic acid 60 was obtained (Scheme 32).  The 
successful conversion of the primary amide to the carboxylic acid allows for the solid support 
products to be utilized in future peptide coupling and peptidomimetics.   
Scheme 32.  Hydrolysis of primary amide 
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2.3 SYNTHESIS OF GAMMA AMINO ACIDS VIA WOLFF REARRANGEMENT 
With successful synthesis of a variety of β2,3-amino acids, we decided to extend our 
methodology to the synthesis of disubstituted γ-amino acids.  The Wolff rearrangement has been 
used with great success to synthesize β-amino acids from α-amino acids via rearrangement of a 
diazoketone.19  This homologation could also be applied to easily ring-opened heterocycles, such 
as the thiazinone and β-lactams.  β-lactams have been shown to undergo ring expansions to γ-
amino acids with reaction of β-lactams with trimethylsilyldiazomethane4.  Ring-opening of our 
heterocycles with trimethylsilyldiazomethane provided the diazoketone in modest yields, which 
was then subject to the silver catalyzed Wolff rearrangement.  The protected γ-amino acid was 
isolated in 41% yield and with the stereochemistry maintained (Scheme 33).  This process gives 
us access to even greater diversity of unnatural highly substituted amino acids.   
Scheme 33.  Synthesis of γ-amino acids via the Wolff rearrangement 
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3.0  CONCLUSION 
Due to the increased interest in β-amino acids and β-peptides for use in peptidomimetics 
and the limited number of naturally occurring β-amino acids, it is necessary to develop 
methodology to synthesize these compounds efficiently and with much variability.  Many of the 
methods of β-amino acid synthesis are based on the Mannich reaction, whereby an enolate adds 
into an imine to form the correct connectivity and substitution while also allowing for diversity 
of stereochemistry and side chains.  Many of the reactions developed to do just that have a 
limited substrate scope.  We successfully developed an asymmetric cycloaddition reaction to 
synthesize heterocycles as masked β-amino acids.  These compounds were synthesized with 
amino acids in mind where the substituents on these β-amino acid precursors mimicked the 
substitution patterns on natural amino acids.  Ring-opening and deprotection reactions were 
developed and allowed for synthesis of multiple peptides in solution and on solid support.  The 
products of these reactions in solution and on solid support can also participate in traditional 
peptide coupling reactions and will add much more versatility in the synthesis of peptidometics.   
 
 
 59 
4.0  EXPERIMENTAL 
General Information:  Optical rotations were measured on a Perkin-Elmer 241 digital 
polarimeter with a sodium lamp and are reported as follows: [a]D (c [g/100 mL], solvent).  
Infrared spectra were recorded on a Nicolet Avatar 360 FT-IR spectrometer.  NMR spectra were 
recorded on a Bruker Avance-300 or -500 as indicated, with chemical shifts reported relative to 
residual CHCl3 (7.26 ppm), CH3OD (3.30 ppm), or pyridine-d5 (8.74) for 1H and CDCl3 (77.0 
ppm), CD3OD (49.2), or pyridine-d5 (150.4) for 13C NMR spectra.  Most compounds bearing an 
O-ethyl carbamothioyl group exist as a mixture of atropisomers in solution; where possible, 1H 
NMR integration values were attributed to either the major (R1) or minor (R2) atropisomer, or a 
mixture of both, based on the atropisomer ratio.  Analytical chiral gas-liquid chromatography 
was performed using a flame ionization detector and split mode capillary injection system with a 
Chirasil - Dex CB column (25 m x 0.25 mm) (Advanced Separation Technologies Inc.).  Helium 
was used as the carrier gas.  Analytical high-performance liquid chromatography (HPLC) was 
performed using a variable wavelength UV detector (deuterium lamp, 190-600 nm) using a 
Chiracel OD-H column and HPLC-grade isopropanol and hexanes as the eluting solvents.  
Melting points are uncorrected. 
All reactions run using General Procedure B were carried out in dry glassware under a 
nitrogen atmosphere using standard inert atmosphere techniques for the manipulation of solvents 
and reagents.  All reactions run using General Procedure F were carried out in disposable 
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polypropylene reaction vessels (syringe with a frit) fitted with a leur slip cap.  NovaPEG Rink 
Amide Resin was purchased from Novabiochem.  Washes and filtrations were done via vacuum 
after removal of the leur slip cap.  Anhydrous solvents (CH2Cl2, THF, DMF, diethyl ether, 
pentane, and toluene) were obtained by passage through successive alumina and Q5 reactant-
packed columns on a solvent purification system.  DIPEA was distilled under a nitrogen  
atmosphere from CaH2. O-Trimethylsilylquinine and  O-trimethylsilylquinidine,32 and 3-(tert-
butyldiphenylsilyloxy (propionaldehyde)33 were prepared according to literature procedures.  
Propionyl chloride was distilled before use.  Column chromatography was performed on EM 
silica gel 60 (230-240 mesh).34 
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General Procedure A: Preparation of a-Amido Sulfones (29a-f): O-Ethyl 
carbamothioate (1 equiv) and sodium p-toluenesulfinate 1.2 equiv) were suspended, with stirring, 
in water (110 mL).  The aldehyde and ~98% formic acid (6.9 equiv) were added, and the reaction 
was stirred vigorously at room temperature.  After 48 h, the reaction was processed in the 
indicated manner.   
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O-Ethyl 3-methyl-1-(p-tosyl)butylcarbamothioate (29a): General Procedure A 
was followed using 10 g of O-ethyl carbamothioate (95 mmol, 1 equiv) and 11.5 
mL of isovaleraldehyde (110 mmol, 1.2 equiv).  The reaction was filtered, and the resulting solid 
was washed with water and pentanes, yielding 25 g (80%) of the title compound as a white 
powder.  mp 100-113 ºC; IR (thin film): 3298, 2959, 2871, 1597, 1521, 1468, 1444, 1372, 1303, 
1258, 1201, 1142, 1085 cm–1; 1H NMR (400 MHz, CDCl3) Atropisomer ratio: 2:3 (R2:R1) δ 7.81 
(d, J = 8.0 Hz, 1.4H (R2)), 7.77 (d, J = 8.4 Hz, 2H (R1)), 7.36 (d, J = 8.4 Hz, 1.4H (R2)), 7.30 (d, 
J = 8.0 Hz, 2H (R1)), 6.85 (br d, J = 9.6 Hz, 0.6H (R2)), 6.54 (d, J = 10.4 Hz, 1H (R1)), 5.74 (dt, J 
= 11.6, 3.2 Hz, 1H (R1)), 5.05 (dt, J = 11.6, 3.2 Hz, 0.7H (R2)) 4.35-4.18 (m, 2.75H (R1 + R2)), 
3.88-3.80 (m, 0.7H (R2)), 2.43-2.42 (m, 5.3H (R1 + R2)), 2.09-1.96 (m, 1.8H (R1 + R2)), 1.86-
1.70 (m, 3.5H (R1 + R2)), 1.20 (t, J = 6.8Hz, 3H (R1)), 1.00-0.96 (m, 10.5H (R1 + R2)), 0.89 (d, J 
= 6.4 Hz, 2.2H, (R2)); 13C NMR (100 MHz) δ 190.9, 189.3, 145.3, 145.1, 133.7, 133.6, 129.8, 
129.6, 129.5, 129.5, 72.7, 70.9, 68.1, 67.0, 35.0, 34.5, 24.7, 24.6, 23.3, 23.1, 21.7, 21.7, 21.6, 
20.9, 14.0, 13.5; HRMS (ES) m/z calcd for C15H23NO3NaS2 (M+Na)+: 352.1017; found: 
352.1048. 
 
O-Ethyl 3-(t-butyldiphenylsilyloxy)-1-(p-tosyl)propylcarbamo-thioate 
(29b): General Procedure A was followed using 8.45 g of O-ethyl 
carbamothioate (25.7 mmol, 3.3 equiv) and 2.42 g of 3-(tert-butyldiphenylsilyloxy) 
propionaldehyde (7.8 mmol, 1 equiv).  After 48 h, 50 mL of methylene chloride was added, the 
layers were separated, and the organic portion was dried and concentrated.  The residue was 
triturated with diethyl ether and pentane, yielding 3.66 g (84%) of the title compound as a white 
solid.  mp 121-124 ºC; IR (thin film): 3301, 2957, 2931, 2858, 1711, 1596, 1521, 1472, 1428, 
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1375, 1316, 1203, 1145, 1109 cm–1; 1H NMR (400 MHz, CDCl3) Atropisomer ratio: 0.9:1 
(R2:R1) δ 7.83 (d, J = 8.4 Hz, 2.0H, (R1)), 7.78 (d, J = 8.0 Hz, 1.9H (R2)), 7.68-7.62 (M, 6H (R1 
+ R2)), 7.59-7.56 (m, 2.1H (R1 + R2)), 7.45-7.35 (m, 14.3H (R1 + R2)), 7.31 (d, J = 8 Hz, 2H 
(R1)), 6.92 (d, J = 10.8 Hz, 0.9H (R2)), 6.86 (d, J = 10.8 Hz, 1H (R1)), 6.00 (ddd, J = 14.0 9.2, 
3.6 Hz, 0.9H (R2)), 5.49 (dt, J = 10.4, 3.2 Hz, 1H (R1)), 4.32 (m, 1.8H (R1 + R2)), 4.14 (dq, J = 
10.4, 6.8 Hz, 1H (R1)), 3.98-3.83 (m, 2.3H (R1 + R2)), 3.81-3.76 (m, 3H (R1 + R2)), 2.59-2.46 
(m, 1.7H (R1 + R2)), 2.45-2.44 (m, 6H (R1 + R2)), 2.09 (app ddd, J = 18.4, 8.8, 4.4, 1H (R1)), 
1.82 (dddd, J = 13.6, 6.4, 3.6, 3.6 Hz, 1H (R1)), 1.23 (t, J = 7.2 Hz, 3H), 1.03-1.03 (m, 17H (R1 + 
R2)), 0.92 (t, J = 7.2 Hz, 3H)  13C NMR (100 MHz) δ 190.9, 189.7, 145.3, 145.2, 135.6, 135.5, 
135.5, 135.3, 134.0, 134.0, 133.0, 132.9, 132.7, 129.9, 129.9, 129.8, 129.8, 129.8, 129.7, 127.8, 
127.7, 127.7, 72.1, 69.4, 68.3, 67.0, 59.8, 58.7, 30.0, 29.5, 26.7, 26.7, 21.7, 21.6, 19.1, 19.0, 14.0, 
13.3; HRMS (ES) m/z calcd for C29H37NO4NaSiS2 (M+Na)+: 578.1831; found: 578.1835. 
 
 
O-Ethyl 3-phenyl-1-(p-tosyl)propylcarbamothioate (29c): General Procedure 
A was followed using 10.0 g of O-ethyl carbamothioate (95 mmol, 1 equiv) and 
14 mL of hydrocinnamaldehyde (106 mmol, 1.1 equiv).  The reaction was filtered, and the 
resulting solid was washed with water and pentanes, yielding 31.6 g (88%) of the title compound 
as a wet white solid.  IR (thin film): 3303, 3026, 2982, 2930, 2865, 1598, 1519, 1453, 1374, 
1304, 1204, 1144, 1084, 1059 cm –1; 1H NMR (400 MHz, CDCl3) Atropisomer ratio 0.9:1 
(R2:R1) δ 7.75-7.72 (m, 3.9H (R1 + R2)), 7.34-7.28 (m, 7.8H (R1 + R2)), 7.24-7.12 (m, 8.3H (R1 + 
R2)), 6.68 (d, J = 10.8 Hz, 0.9H (R2)), 6.43 (d, J = 10.8 Hz, 1H, R1), 5.74 (dt, J = 3.6 Hz, 1H, 
R1), 4.88 (dt, J = 3.6 Hz, 0.9H, R2), 4.36-4.24 (m, 2H, R1), 4.18-4.09 (m, 1H, R2), 3.80 (dq, J = 
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10.8, 7.2 Hz, 0.9H, R2), 2.96-2.88 (m, 1H), 2.84-2.56 (m, 6.8, (R1 + R2)), 2.43 (app s, 6H (R1 + 
R2)), 2.20-2.01 (m, 3H (R1 + R2)), 1.22 (t, J = 7.2 Hz, 3H (R1)), 0.90 (t, J = 7.2 Hz, 2.8H (R2)); 
13C NMR (100 MHz, CDCl3) δ 191.2, 189.5, 145.2, 145.2, 139.9, 139.0, 129.7, 129.6, 128.5, 
128.5, 128.4, 128.4, 128.2, 126.5, 126.3, 73.6, 71.2, 68.0, 67.0, 31.3, 31.1, 28.5, 27.5, 21.6, 21.5, 
14.0, 13.3; HRMS (ES) m/z calcd for C19H23NONaS2 (M+Na)+: 400.1017; found: 400.1052. 
 
O-Ethyl(5-(1,3-dioxoisoindolin-2-yl)-1-tosylpentyl)carbamothioate    
(29d): General Procedure A was followed using 0.317 g of O-ethyl 
carbamothioate (3.02 mmol, 1 equiv) and 0.700 g of 5-(1,3-dioxo- 
isoindolin-2-yl)pentanal (3.02 mmol, 1 equiv).  The reaction mixture was extracted with DCM, 
dried and concentrated to afford 1.31 g of yellow oil was obtained.  After flash chromatography 
(10% EtOAc: Hex), 0.99 g (69%) of desired compound was isolated as a white solid.   IR (thin 
film): 3292, 2933, 1770, 1709, 1519, 1398, 1372, 1201, 1143 cm –1; 1H NMR (400 MHz, CDCl3) 
Atropisomer ratio 0.6:1 (R2:R1) δ 7.86-7.69 (m, 10H (R1+R2)), 7-34-7.29 (m, 3.3H (R1+R2)),  
6.72 (d,  J = 10.8 Hz, 0.6H (R2)), 6.48 (d, J = 3.6 Hz, 1H (R1)), 5.68 (dt, J = 3.2, 11.2 Hz, 1H 
(R1)), 4.96 (dt, J = 3.2, 11.2 Hz, 0.6H (R2)), 4.30-4.25 (m, 2.5H (R1+R2)), 3.86-3.80 (m, 0.6H 
(R2)), 3.73-3.67 (m 3.6H (R1+R2)), 2.44 (s, 1.7H (R2)), 2.43 (s, 3H (R1)), 2.32 (m, 1.8H 
(R1+R2)), 1.99-1.60 (m, 5.6H (R1+R2)), 1.55-1.40 (m, 3.8H, (R1+R2)), 1.19 (t, J = 7.2 Hz, 3H 
(R1)), 0.96 (t, J = 7.2 Hz, 2H (R2)); 13C NMR (100 MHz, CDCl3) δ 191.2, 189.5, 171.1, 168.4, 
168.3, 145.3, 145.1, 133.9, 133.9, 133.7, 133.7, 132.0, 131.9, 129.8, 129.7, 129.4, 129.4, 123.3, 
123.2, 73.5, 71.8, 68.1, 67.0, 60.3, 53.4, 37.0, 36.9, 27.9, 27.6, 25.9, 25.6, 22.4, 22.1, 21.7, 21.6, 
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21.0, 14.1, 13.9, 13.4; HRMS (ES) m/z calcd for C23H27N2O5S2 (M+H)+: 475.1361; found: 
475.1366. 
 
Benzyl 4-((ethoxycarbonothioyl)amino)-4-tosylbutanoate (29e): General 
Procedure A was followed using 0.547 g of O-ethyl carbamothioate (5.2 
mmol, 1 equiv) and 1.0 g of benzyl 4-oxobutanoate (5.2 mmol, 1 equiv).  The reaction mixture 
was extracted with DCM, dried and concentrated to afford 2.09 g of clear oil. After flash 
chromatography (10% EtOAc: hexanes), 1.60 g (71%) of desired compound was isolated as a 
white solid.   IR (thin film): 3289, 2981, 1734, 1596, 1520, 1451, 1304, 1202, 1146, 1083 cm –1; 
1H NMR (400 MHz, CDCl3) Atropisomer ratio 0.5:1 (R2:R1) δ 7.78 (d, J = 8.4 Hz, 1H (R2)), 
7.74 (d, J = 8 Hz, 2H (R1)) 7.38-7.29 (m, 9.5H (R1 + R2)), 6.67 (d, J = 10.4 Hz, 0.5H (R2)), 6.49 
(d, J = 11.2 Hz, 1H), 5.80 (dt, J = 10.8, 3.2 Hz, 1H (R1)), 5.17-5.11 (m, 4H (R1 + R2)), 4.34-
4.24 (m, 2H (R1 + R2)), 3.90-3.85 (m, 0.5H (R2)), 2.70-2.54 (m, 5H (R1 + R2)), 2.44-2.43 (m, 
4.5H (R1 + R2)),  2.22-2.17 (m, 1H (R1)), 2.09-2.04 (m, 0.5H (R2)), 1.20 (t, J = 7.2 Hz, 3H (R1)), 
0.93 (t, J = 7.2 Hz, 1.5H (R2); 13C NMR (100 MHz, CDCl3) δ 191.3, 189.3, 171.7, 171.5, 145.2, 
125.1, 135.4, 135.3, 133.3, 129.6, 129.5, 129.3, 129.2, 128.3, 128.3, 128.1, 128.0, 128.0, 72.9, 
10.9, 67.8, 67.0, 66.4, 60.2, 29.5, 22.1, 21.8, 21.5, 21.4, 20.8, 13.9, 13.7, 13.2; HRMS (ES) m/z 
calcd for C21H26NO5S2 (M+H)+: 436.1252; found: 436.1253. 
 
O-Ethyl (2-(1-benzyl-1H-indol-3-yl)-1-tosylethyl)carbamothioate (29f): 
General Procedure A was followed using 3.80 g of O-ethyl carbamothioate 
(36.1 mmol, 1 equiv) and 9.00 g of 2-(1-benzyl-1H-indol-3-yl)acetaldehyde (36.1 mmol, 1 
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equiv).  The reaction was extracted with DCM, dried, and concentrated.  Flash chromatography 
was performed (10% EtOAc: hexanes) and 3.30 g (19%) of desired compound was obtained as a 
pale red solid was obtained.  IR (thin film): 3295, 3028, 1521, 1468, 1442, 1373, 1356, 1301, 
1202, 1144, 1083, 742 cm –1; 1H NMR (400 MHz, CDCl3) Atropisomer ratio 0.7:1 (R2:R1) δ 7.84 
(d, J = 8 Hz, 1.4H (R2)), 7.79 (d, J = 8.4 Hz, 2H (R1)), 7.60 (d, J = 7.6 Hz, 0.7H (R2)), 7.57 (d, J 
= 7.6 Hz, 1H), 7.37-7.00 (m, 22.7H (R1 + R2)), 6.79 (d, J = 10.8 Hz, 0.7H (R2)), 6.52 (d, J = 10.8 
Hz, 1H (R1)), 6.06 (dt, J = 10.4, 4 Hz, 1H (R1)),  5.33 (dt, J = 10.4, 2.8 Hz, 0.7H (R2)), 5.25 (s, 
3.4H (R1 + R2)), 4.26-4.10 (m, 2H (R1)), 3.92-3.68 (m, 3.4H (R1 + R2)), 3.43 (dd, J = 15.6, 9.6 
Hz, 1H (R1)), 3.16 (dd, J = 14.8, 10.8 Hz, 0.7H (R1 + R2)), 2.44 (s, 2.1H (R2)), 2.43 (s, 3H (R1)), 
1.11 (t, J = 7.2 Hz, 3H (R1)), 0.67 (t, J = 7.2 Hz, 2.1H (R2));  13C NMR (125 MHz, CDCl3) δ 
191.0, 189.4, 145.3, 145.2, 137.3, 137.2, 136.5, 136.4, 133.9, 133.7, 129.9, 129.7, 129.4, 128.7, 
128.6, 128.2, 127.6, 127.5, 127.5, 127.4, 127.1, 126.7, 122.1, 121.9, 119.6, 119.4, 118.6, 118.4, 
110.0, 109.8, 107.4, 107.3, 73.5, 71.8, 67.9, 66.9, 50.0, 23.2, 22.9, 21.7, 21.6, 13.9, 13.1HRMS 
(ES) m/z calcd for C27H29N2O3S2 (M+H)+: 493.1620; found: 493.1649. 
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General Procedure B: Preparation of Thiazinones and β-Lactams:  The a-amido 
sulfone (1 equiv) and O-trimethylsilylquinine or O-trimethylsilylquinidine (0.20 equiv) were 
dissolved in methylene chloride (0.03 M) and cooled to –78 °C with stirring.  N, N-
diisopropylethylamine (3.6 equiv) was added.  A solution of lithium iodide (0.7 equiv) in diethyl 
ether (0.5 M) was added in one portion, followed by propionyl chloride (0.51 equiv) in 
methylene chloride (4 M) over 20 min.  One hour after addition, an identical portion of lithium 
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iodide in diethyl ether was added at once, followed by an identical portion of propionyl chloride 
in dichloromethane over 20 min.  This process was repeated 3 times.  After 16 h, acetic acid (1.5 
equiv) in diethyl ether (1.9 M) was added, and the reaction was immediately extracted with 
saturated NH4Cl(aq) (3 x 50 mL).  The aqueous portion was extracted with diethyl ether (50 mL), 
the combined organic portion was washed with brine (3 x 30 mL), and passed through a silica gel 
plug, eluting with diethyl ether.  The eluent was then concentrated and purified by column 
chromatography. 
 
(4S,5R)-2-Ethoxy-4-isobutyl-5-methyl-4H-1,3-thiazin-6(5H)-one 
(30a) and (2R,3R)-O-ethyl 2-isobutyl-3-methyl-4-oxoazetidine-1-
carbothioate (31a): General Procedure B was followed using 
2.03g of 29a (6.18 mmol) and 2.30 g of propionyl chloride (24.7 mmol).  Flash column 
chromatography (2% to 3% ethyl acetate in hexanes) afforded 1.12 g (79%) of 30a as a colorless 
oil and 0.139 g of 31a (9.7%) as a colorless oil. 
 
30a: Separating the enantiomers by chiral GLC [Chirasil - Dex CB column (25 m x 0.25 
mm), flow rate 0.6 mL/min, method: 105 °C for 10 min, ramp @ 0.7 °C/min to 160 °C, hold for 
5 min; Tr 51.6 min (4R,5S) and 53.8 min(4S,5R)] provided the enantiomer ratio: 4S,5R:4R,5S > 
100:1 (>99% ee); [α]23D   –37.3 (c 1.1, CHCl3); IR (Thin Film) 2956, 2870, 1707, 1657, 1463, 
1385, 1193, 1136 cm–1; 1H NMR (300 MHz, CDCl3) δ 4.29 (q, J = 7.2 Hz, 2H), 3.73 (dt, J = 7.8, 
3.9 Hz, 1H), 2.59 (dq, J = 7.2, 3.6 Hz, 1H), 1.90-1.77 (m, 1H), 1.64-1.54 (m, 1H), 1.32 (t, J = 6.9 
Hz, 3H), 1.17 (ddd, J = 13.2, 9.0, 4.2 Hz, 1H), 1.08 (d, J = 7.2 Hz, 3H), 0.93 (app dd, J = 6.6, 2.8 
Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 200.2, 153.4, 64.2, 64.1, 58.2, 56.6, 45.6, 45.3, 45.1, 
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42.5, 39.5, 24.7, 24.6, 23.4, 23.2, 21.6, 14.2, 14.1, 10.0; HRMS (ES) m/z calcd for C11H20NO2S 
(M+H)+: 230.1215; found: 230.1215. 
 
31a: Separating the enantiomers by chiral GLC [Chirasil - Dex CB column (25 m x 0.25 
mm), flow rate 0.6 mL/min, method: 105 °C for 10 min, ramp @ 0.7 °C/min to 160 °C, hold for 
5 min; Tr 63.0 min (2R,3R) and 74.1 min (2S,3S)] provided the enantiomer ratio: 2R,3R:2S,3S =  
96.1:1 (98–103.5 (% ee); [α]23D   c 1.7, CHCl3); IR (Thin Film) 2959, 2872, 1798, 1465, 1349, 
1310, 1275, 1251, 1222 cm–1; 1H NMR (300 MHz, CDCl3) δ 4.58 (q, J = 7.2 Hz, 2H), 3.30 (dt, J 
=  6.3, 3.3 Hz, 1H), 2.84 (dq, J = 7.5, 3.3 Hz, 1H) 2.38 (ddd, J = 12.6, 9, 3.3 Hz, 1H), 1.75-1.63 
(m, 1H), 1.44-1.36 (m, 6H), 0.98 (app dd, J = 6.6, 3.6 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 
185.2, 166.2, 67.6, 61.5, 50.1, 40.4, 25.5, 23.4, 22.0, 13.7, 13.2; HRMS (ES) m/z calcd for 
C11H19NO2NaS (M+Na)+: 252.1034; found: 252.1051. 
 
(4S,5R)-4-[2-(t-Butyldiphenylsilyloxy)ethyl]-2-ethoxy-5-
methyl-4H-1,3-thiazin-6(5H)-one (30b) and (2R,3R)-O-
ethyl 2-[2-(t-butyldiphenyl-silyloxy)ethyl]-3-methyl-4-oxoazetidine-1-carbothioate (31b): 
General Procedure B was followed using 1.30 g of 29b (2.34 mmol) and 0.87 g of propionyl 
chloride (9.4 mmol).  Flash column chromatography (2% ethyl acetate in hexanes) afforded 
0.480 g (46%) of 30b as a colorless oil and 0.400 g of 31b (38%) as a colorless oil. 
 
30b: Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 0.8 ml/min, 0% iPrOH, 100% hexanes, hold for 5 min, 0.5% iPrOH, 99.5% hexanes hold for 
20 min, 1% iPrOH, 99% hexanes hold for 10 min, Tr 20.9 min (4R,5S) and 30.7 min (4S,5R)] 
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provided the enantiomer ratio: (4S,5R):(4R,5S) 97:3 (94% ee);  [α]23D   –22.7 (c 1.1, CHCl3); IR 
(Thin Film) 3070, 2928, 2854, 1707, 1656, 1470, 1427, 1388, 1189 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.69-7.66 (m, 4H), 7.45-7.36 (m, 6H) 4.16 (q, J = 7.2 Hz); 3.94-3.80 (m, 3H), 2.63 (dq, 
J = 7.2, 3.6 Hz), 1.82-1.70 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H), 1.06 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 200.3, 153.9, 135.6, 135.5, 133.7, 133.7, 129.6, 129.6, 127.6, 127.6, 64.3, 60.6, 55.0, 
45.1, 34.0, 26.8, 19.2, 14.1, 10.0; HRMS (ES) m/z calcd for C25H3NO3NaSiS (M+Na)+: 
478.1848; found: 478.1829. 
 
31b: Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 0.8 ml/min, 1% iPrOH, 99% hexanes, Tr 8.2 min (2R,3R) and 8.9 min (2S,3S)] provided the 
enantiomer ratio: (2R,3R):(2S,3S) 97:3 (94% ee); [α]23D   –38 (c 1.3, CHCl3); IR (Thin Film) 2958, 
2932, 2858, 1798, 1472, 1428, 1372, 1346, 1298, 1278 cm–1; 1H NMR (300 MHz, CDCl3) δ 
7.70-7.63 (m, 4H), 7.47-7.37 (m, 6H), 4.57 (q, J = 7.2 Hz, 2H), 3.92 (dt, J = 6.3, 3.3 Hz, 1H) 
3.79 (t, J = 5.7 Hz, 2H), 3.09 (dq, J = 7.5, 3.3 Hz, 1H), 2.69 (m, 1H), 1.75 (dddd, J = 14.1, 9.9, 
5.7, 5.7 Hz, 1H), 1.41 (t, J = 7.2 Hz, 3H), 1.35 (d, J = 7.5 Hz, 3H), 1.05 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ 185.3, 166.4, 135.4, 133.2, 133.1, 29.8, 127.7, 67.7, 61.2, 60.8, 49.9, 33.8, 26.7, 
19.0, 23.7, 13.1; HRMS (ES) m/z calcd for C25H3NO3NaSiS (M+Na)+: 478.1848; found: 
478.1830. 
 
(4S,5R)-2-Ethoxy-5-methyl-4-phenethyl-4H-1,3-thiazin-6(5H)-
one (30c) and (3R,4R)-O-ethyl 3-methyl-2-oxo-4-phenethyl-
azetidine-1-carbothioate (31c): General Procedure B was 
followed using 2.12 g of 29c (5.62 mmol) and 1.06 g of propionyl chloride (11.4 mmol).  Flash 
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column chromatography (2% to 3% ethyl acetate in hexanes) afforded 0.824 g (54%) of 30c as a 
colorless oil and 0.487 g of 31c (32%) as a colorless oil. 
30c: Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 1.0 ml/min, 2% iPrOH, 98% hexanes, Tr 7.0 min (4R,5S) and 11.0 min (4S,5R) min] 
provided the enantiomer ratio: (4S,5R):(4R,5S) = 68.6:1 (97% ee); [α]23D   –88.3 (c 1.3, CHCl3); IR 
(Thin Film) 2981, 2940, 1705, 1657, 1496, 1454, 1384, 1202 cm–1; 1H NMR (400 MHz, CDCl3) 
δ 7.37-7.34 (m, 2H), 7.28-7.26 (m, 3H), 4.41 (q, J = 7.2H, 2H), 3.69 (dt, J = 7.2, 3.6 Hz, 1H), 
2.98 (ddd, J = 14, 9.2, 4.8 Hz, 1H) 2.82-2.75 (m, 1H), 2.65 (dddd, J = 10.8, 7.2, 7.2, 3.6 Hz, 1H), 
2.05-1.98 (m, 1H), 1.84-1.76 (m, 1H), 1.43 (t, J = 7.2 Hz, 3H), 1.14 (d, J = 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 199.9, 153.8, 141.5, 128.3, 128.3, 125.8, 64.3, 57.6, 32.7, 32.4, 14.1, 
9.9; HRMS (ES) m/z calcd for C15H20NO2S (M+H)+: 278.1215; found: 278.1195. 
 
31c: Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 1.0 ml/min, 2% iPrOH, 98% hexanes, Tr 14.8 min (2S,3S) and 23.2 min (2R,3R)] provided 
the enantiomer ratio: (2R,3R):(2S,3S) >100:1 (>98% ee); [α]23D   –60 (c 1.4, CHCl3); IR (Thin 
Film) 2931, 1796, 1724, 1453, 1372, 1311, 1277 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.35-7.30 
(m, 2H), 7.26-7.23 (m, 2H), 4.60 (q, J = 7.2 Hz, 2H), 3.80 (dt, J = 5.6, 2.8 Hz, 1H), 2.91-2.78 
(m, 2H), 2.73 (t, J = 8.4 Hz, 2 H) 1.99-1.90 (m, 1H), 1.44 (t, J = 7.2 Hz, 3H), 1.31 (d, J = 7.2 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 185.2, 165.7, 140.2, 128.4, 128.1, 126.1, 67.6, 61.9, 49.4, 
32.3, 31.0, 13.6, 12.9; HRMS (ES) m/z calcd for C15H19NO2NaS (M+Na)+: 300.1034; found: 
300.1039.  
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2-(4-((4S,5R)-2-Ethoxy-5-methyl-6-oxo-5,6-dihydro-4H-1,3-
thiazin  4-yl)butyl)isoindoline-1,3-dione (30d):  General Procedure 
B was followed using 0.500 g of 29d (1.05 mmol) and 0.198 g of 
propionyl chloride (2.10 mmol).  Flash chromatography (5% EtOAc in Hexanes) afforded 0.131 
g (55%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.85-7.82 (m, 2H), 7.73-7.71 (m, 2H), 
4.25 (q, J = 6.8 Hz, 2H), 3.70 (t, J = 7.2 Hz, 2H), 3.61-3.60 (m, 1H), 2.63-2.57 (m, 1H), 1.77-
1.70 (m, 2H), 1.69-1.57 (m, 2H), 1.55-1.45 (m, 2H), 1.29 (t,  J = 7.2 Hz, 3H), 1.08 (d, J = 6.8 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 200.3, 168.4, 153.9, 133.9, 132.1, 123.2, 64.4, 58.6, 
45.2, 37.8, 30.5, 28.3, 23.8, 14.1, 10.0; HRMS (ES) m/z calcd for C19H23N2O4S (M+H)+: 
375.1379; found: 375.1364. 
3-((4S,5R)-2-Ethoxy-5-methyl-6-oxo-5,6-dihydro-4H-1,3-
thiazin-4-yl)propanoate (30e): and Benzyl 3-((2R,3R)-1-
(ethoxy-carbonothioyl)-3-methyl-4-oxoazetidin-2-yl) 
propanoate (31e) General Procedure B was followed using 0.500 g of 29e (1.15 mmol) and 
0.205 g of propionyl chloride (2.30 mmol).  Flash column chromatography (2% to 3% ethyl 
acetate in hexanes) afforded 0.187 g (48%) of 30e as a colorless oil and 0.093 g of 31e (24%) as 
a colorless oil. 
 
30e: Separating the enantiomers by chiral GLC [Chirasil - Dex CB column (25 m x 0.25 
mm), flow rate 3.0 mL/min, method: 105 °C for 10 min, ramp @ 3.0 °C/min to 225 °C, hold for 
30 min; Tr 48.76 min (4S,5R) and 48.56 min (4R,5S)] provided > 99% ee (4R,5S enantiomer was 
not detected) ; [α]23D   –12.8 (c 3.2, CHCl3); IR (Thin Film) 2980, 1735, 1706, 1656, 1499, 1454, 
1384, 1350, 1194, 1164, 1141, 1020 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.36-7.33 (m, 5H), 
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5.13 (s, 2H), 4.27 (q, J  = 7.2 Hz, 2H), 3.63 (dt,  J = 7.2, 3.6 Hz, 1H), 2.66-2.51 (m, 3H), 1.98-
1.88 (m, 1H), 1.87-1.75 (m, 1H), 1.31 (t, J = 7.2 Hz, 3H), 1.09 (d, J = 7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 199.8, 173.0, 154.5, 135.8, 128.5, 128.5, 128.2, 128.2, 128.1, 66.18, 64.4, 
57.6, 45.1, 31.0, 26.4, 14.0, 9.7; HRMS (ES) m/z calcd for C17H22NO4S (M+H)+: 336.1270; 
found: 336.1310. 
 
31e Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 1.0 ml/min, 1% iPrOH, 99% hexane, Tr 24.7 min (3R,4R) and 28.1 min (3S,4S) min] 
provided >99% ee (enantiomer 3S,4S was not detected); [α]23D   –64 (c 0.7, CHCl3); IR (Thin 
Film) 2976, 1797, 1735, 1454, 1347, 1293, 1165, 1100, 1073, 1010 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.38- 7.31 (m, 5H), 5.13 (s, 2H), 4.57 (q, J = 7.2 Hz, 2H), 3.77 (dt, J = 9.2, 3.2 Hz, 
1H), 2.87 (dq, J = 7.6, 3.6 Hz, 1H), 2.73-2.66 (m, 1H), 2.45 (t, J = 7.2 Hz, 2H), 2.01-1.92 (m, 
1H),  1.40 (t, J = 7.2 Hz, 3H), 1.08 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 185.4, 172.4, 165.6, 135.5, 128.5, 128.5, 128.4, 128.3, 128.2, 67.9, 66.6, 61.4, 49.3, 30.0, 26.6, 
13.7, 12.9; HRMS (ES) m/z calcd for C17H22NO4S (M+H)+: 336.1270; found: 336.1304.  
 
(4S,5R)-4-((1-Benzyl-1H-indol-3-yl)methyl)-2-ethoxy-5-
methyl-4,5-dihydro-6H-1,3-thiazin-6-one (30f) and O-Ethyl 
(2R,3R)-2-((1-benzyl-1H-indol-3-yl)methyl)-3-methyl-4-oxo- 
aze tidine-1--carbothioate (31f): General Procedure B was followed using 0.500 g of 29f (1.02 
mmol) and 0.193 g of propionyl chloride (2.04 mmol).  Flash column chromatography (2% to 
3% ethyl acetate in hexanes) afforded 0.048 g (12%) of 30f as a colorless oil and 0.108 g of 31f 
(27%) as a colorless oil. 
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30f: Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 1.0 ml/min, 2% iPrOH, 98% hexanes, Tr 8.1 min (4S,5R) and 17.2 min (4R,5S) min] 
provided >99% ee (enantiomer 4R,5S was not detected); [α]23D   +10.0 (c 0.2 CHCl3); IR (thin 
film) 2927, 1702, 1656, 1466, 1358, 1185, 1115, 1017 cm–1; 1H NMR (300 MHz, CDCl3) δ 7.62 
(d, J = 7.5 Hz,  1H), 7.35-7.10 (m, 10H), 7.02 (s, 1H), 5.31 (s, 2H),  4.25 (dq, J = 7.2, 1.5 Hz, 
2H), 4.01 (dt, J = 8.1, 3.3 Hz, 1H), 3.20 (dd, J = 14.7, 8.4 Hz, 1H), 3.04 (dd, J = 14.4, 6.6 Hz, 
1H), 2.70 (ddd, J = 7.2, 6.9, 3.3 Hz, 1H), 1.30 (t, J = 6.9 Hz, 3H), 1.21 (d, J = 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 200.6, 154.3, 137.5, 136.6, 128.9, 128.8, 128.7, 128.2, 127.6, 126.8, 
126.6, 121.8, 119.1, 119.0, 111.6, 109.7, 64.4, 59.4, 49.9, 44.3, 14.1, 9.7; HRMS (ES) m/z calcd 
for C23H25N2O2S (M+H)+: 393.1637; found: 393.1669. 
 
31f: Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, flow 
rate 1.0 ml/min, 1% iPrOH, 99% hexanes, Tr 49.8 min (3R,4R) and 54.5 min (3S,4S) min] 
provided >99% ee (enantiomer 3S,4S  was not detected); [α]23D   –1.0 (c 2.0, CHCl3); IR (thin film) 
2978, 1794, 1495, 1466, 1345, 1315, 1285, 1243, 1138, 1095, 1014 cm–1; 1H NMR (500 MHz, 
CDCl3) δ 7.82 (d, J = 8 Hz, 1H), 7.32-7.10 (m, 9H),  6.93 (s, 1H), 5.29 (s, 2H),  4.71-4.59 (m, 
3H), 4.02 (dd, J = 14.5, 2 Hz, 1H), 3.39 (app p, J = 7 Hz, 1H), 2.96 (dd, J = 15, 11.5 Hz, 1H), 
1.45 (t, J = 7 Hz, 3H), 1.28 (d, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 185.4, 166.4, 
137.4, 136.6, 128.8, 127.9, 127.7, 126.7, 126.1, 122.2, 119.4, 119.4, 110.4, 109.8, 67.9, 57.2, 
49.9, 46.8, 23.0, 13.8; HRMS (ES) m/z calcd for C23H25N2O2S (M+H)+: 393.1637; found: 
393.1672 
 
 73 
(4R,5S)-2-Ethoxy-5-methyl-4-phenethyl-4H-1,3-thiazin-6(5H)-one (ent-30c): 
Separating the enantiomers by chiral HPLC [Daicel Chiralpak OD-H column, 
flow rate 1.0 ml/min, 2% iPrOH, 98% hexane, Tr 7.0 min (4R,5S) and 11.0 min (4S,5R) min] 
provided the enantiomer ratio: (4R,5S):(4S,5R) > 100:1 (>98% ee).  [α]23D   36 (c 1.5, CHCl3). 
 
(4R,5S)-2-Ethoxy-4-isobutyl-5-methyl-4H-1,3-thiazin-6(5H)-one (ent-30a): 
Separating the enantiomers by chiral GLC [Chirasil - Dex CB column (25 m x 
0.25 mm), flow rate 0.6 mL/min, method: 105 °C for 10 min, ramp @ 0.7 °C/min to 160 °C, 
hold for 5 min; Tr 51.6 min (4R,5S) and 53.8 min (4S,5R)] provided the enantiomer ratio: 
4S,5R:4R,5S > 100:1 (>99% ee).  [α]23D   42 (c 1.6, CHCl3). 
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General Procedure C: Ring-opening of Thiazinones and β-Lactams with Methanol: 
The thiazinone or β-lactam (1 equiv) was dissolved in methanol at ambient temperature.  N, N-
diisopropylethylamine (1.5 equiv) was added.  After 20 min, the reaction was concentrated in 
vacuo to afford the product, which could be purified by column chromatography, or used without 
further purification. 
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General Procedure D: Deprotection of β-Amino Acid Derivatives:  To the protected 
substrate (1 equiv) was added THF, acetone, and H2O (2:1:1 v:v, 0.2 M) with vigorous stirring.  
The mixture was cooled to 0 °C, and Oxone (1.5 equiv) was added all at once.  After 5 min, the 
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reaction was warmed to ambient temperature, and allowed to stir for 20 min.  The reaction was 
then cooled to 0 °C, and saturated K2CO3(aq) was added slowly to pH 11.  The heterogeneous 
mixture was then concentrated in vacuo, and enough water was added to the residue to create a 
homogeneous solution.  The aqueous portion was then extracted with 5:1 chloroform:isopropanol 
or ethyl acetate.  The combined organics were then dried (Na2SO4) and concentrated to afford the 
crude product, which can be used without further purification. 
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General Procedure E: Ring-Opening of Thiazinones or β-Lactams with a β-Amino 
Acid Derivative: To a stirring mixture of the β-amino acid derivative (1 equiv) and thiazinone or 
β-lactam in acetonitrile was added a trace amount of 4-(dimethylamino)pyridine.  The reaction 
was then stirred overnight at ambient temperature, concentrated in vacuo, and purified in the 
indicated manner. 
 
(2R,3S)-Methyl 3-(ethoxycarbonothioylamino)-2-methyl-5-phenyl-pentan-
oate (MeO-(30c)-NHC(S)OEt):  General Procedure C was followed using 
252 mg of 30c (0.91 mmol) and 0.34 mL of iPr2NEt (1.4 mmol).  The solvent was removed in 
vacuo to yield 272 mg (97%) of the title compound as a clear, colorless oil that was used without 
further purification.  [α]23D   –9.0 (c 3.0, CHCl3). IR (thin film): 3320, 3027, 2980, 2985, 1735, 
1518, 1435, 1400, 1382, 1334, 1257, 1177 cm-1; 1H NMR (400 MHz, CDCl3) Atropisomer ratio: 
2:3 (R2:R1) δ 7.28-7.16 (m, 6.6 H (R1 + R2)), 6.71 (br d, J = 9.6 Hz, 0.6 H (R1)), 4.59-4.47 (m, 3 
H (R1 + R2)), 4.13-4.10 (m, 0.5H), 3.68 (s, 3H (R1 + R2)), 2.90-2.88 (m, 0.7 H (R1)), 2.77-2.60 
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(m, 3.1 H (R1 + R2)), 1.82-1.75 (m, 3.8H (R1 + R2)), 1.33 (dt, J = 6.8, 6.4 Hz, 3.3 H (R1 + R2)), 
1.21-1.6 (m, 3.4H (R1 + R2)); 13C NMR (100 MHz, CDCl3) δ 190.2, 189.9, 174.5, 174.2, 141.3, 
140.6, 128.3, 128.3, 128.2, 126.0, 125.9, 67.7, 66.2, 56.9, 54.5, 51.8, 51.7, 44.1, 42.7, 33.7, 32.5, 
32.4, 32.2, 14.1, 14.1, 13.8, 13.6; HRMS (ES) m/z calcd for C16H23NO3NaS (M+Na)+: 332.1296; 
found: 332.1281. 
 
 (2R,3S)-Methyl 3-amino-2-methyl-5-phenylpentanoate (MeO-(30c)-NH2): 
General Procedure D was followed using 0.242 g of 7 (0.78 mmol) and 0.721 g of 
Oxone® (1.2 mmol).  The title compound was obtained as a clear oil in 100% yield (0.181 g). 
[α]23D   –21 (c 1.7, CHCl3); IR (thin film):  3359, 3026, 2981, 2949, 1725, 1506, 1454, 1401, 1302, 
1208, 1177, 1101 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31-7.25 (m, 2H), 7.20-7.15 (m, 3H), 
3.68 (s, 3H), 3.07 (dt, J = 9.0, 4.5 Hz, 1H), 2.81 (ddd, J = 15.6, 10.2, 5.7 Hz, 1H), 2.67-2.49 (m, 
2H), 1.83-1.53 (m, 2H), 1.14 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.9, 141.8, 
128.4, 128.3, 125.8, 52.6, 51.6, 45.2, 37.0, 32.9, 11.0; HRMS (ES) m/z calcd for C13H20NO2 
(M+H)+: 222.1494; found: 222.1481. 
 
 (2R,3S)-Methyl 3-(ethoxycarbonothioylamino)-2,5-dimethyl-hexanoate 
(44):  General Procedure C was followed using 0.724 g of 30a (3.16 mmol) 
and 0.82 mL of iPr2NEt (4.74 mmol).  The crude oil was purified by flash chromatography (5% 
EtOAc/hexanes on silica gel) to afford 0.746 g (90%) of the title compound as a clear colorless 
oil.  [α]23D   –54 (c 3.3, CHCl3). IR (thin film): 3317, 2955, 2871, 1737, 1523, 1194 cm
-1; 1H NMR 
(400 MHz, CDCl3) Atropisomer ratio: 2:3 (R2:R1) δ 6.67 (br d, J = 9.6 Hz, 0.6H (R2)), 6.50 (br d, 
J = 9.6Hz, 1H (R1)), 4.63 – 4.50 (m, 2.3H (R1+R2)), 4.44 (dq, J = 1.6, 4.8Hz, 2H (R1)), 4.21 – 
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4.13 (m, 0.6H, R2), 3.70 (s, 2H (R2)), 3.69 (s, 3H (R1)), 2.86 (dq, J = 4.0, 7.2Hz, 1H (R1)), 2.55 
(app quint, J = 6.8Hz, 0.6H (R2), 1.68 – 1.57 (m, 2H (R2)), 1.45 – 1.24 (m, 8H (R1+R2)), 1.19 (d, 
J = 7.2Hz, 3H (R1)), 1.16 (d, J = 7.2Hz, 2H (R1)), 0.95 – 0.87 (m, 10H (R1+R2)); 13C NMR (75 
MHz, CDCl3) δ 189.8, 189.4, 174.4, 174.3, 67.6, 66.1, 55.2, 52.2, 51.7, 51.6, 44.4, 42.6, 41.4, 
39.4, 24.8, 24.5, 23.3, 23.3, 21.8, 21.0, 14.1, 13.7, 13.5; HRMS (ES) m/z calcd for C12H23NO3S 
(M+Na)+: 284.1296; found: 284.1271. 
 
 (2R,3S)-Methyl 3-amino-2,5-dimethylhexanoate (45): General Procedure D 
was followed using 0.265 g of 44 (1.01 mmol) and 0.934g of Oxone® (1.52 
mmol).  An acid/ base extraction was done and 0.128 g (73%) of the title compound was 
obtained as a clear colorless oil.  [α]23D   –31 (c 1.8, CHCl3) IR (thin film):  3363, 2955, 2871, 
1735, 1199 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.65 (s, 3H), 3.08 (app. quintet, J = 4.4 Hz, 1H), 
2.40 (dq, J = 4.4, 7.2 Hz, 1H), 1.72–1.61 (m, 1H), 1.23 – 1.16 (m, 2H), 1.14-1.10 (m, 1H), 1.08 
(d, J = 7.2 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 176.1, 51.5, 50.5, 45.2, 44.4, 24.8, 23.4, 21.7, 10.8; HRMS (ES) m/z calcd for 
C9H19NO2 (M+Na)+: 196.1313; found: 196.1328. 
 
(2R,3S)-Methyl-3-[(2R,3S)-3-(ethoxycarbonothioylamino)-2,5 di-  
methyl-hexanamido]-2,5-dimethylhexanoate (MeO-(30a-30a) 
NHC(S)OEt): General Procedure E was followed using 0.252g of 45 (1.45 mmol, 1 equiv) and 
0.296g of 30a (1.31 mmol, 0.9 equiv).  The residue was dissolved in methylene chloride and 
washed with 1 M HCl.  The organic portion was then dried (Na2SO4) and concentrated in vacuo 
to obtain 0.493 g (93%) of the title compound as a white solid.  mp: 170 °C (dec); [a]23D   –65 (c 
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1.0, CHCl3) IR (thin film): 3364, 3254, 2956, 2871, 1714, 1657, 1535, 1186, 1137 cm-1, 1H 
NMR (300 MHz, CDCl3) Atropisomer ratio: 3:2 (R1:R2) δ 6.71–6.66 (m, 0.9H (R1+R2)), 5.89 (br 
d, J = 9.3 Hz, 0.6H (R1)), 5.78 (br d, J = 9.6 Hz, 0.4H (R2)), 4.65-4.48 (m, 0.8H (R1+R2)), 4.47-
4.38 (m, 1.8H (R1+R2)), 4.27-4.10 (m, 1.3H (R1+R2)), 3.69-3.68 (m, 3H (R1+R2)), 2.77 (dq, J = 
5.1, 7.2Hz, 0.6H (R2)), 2.63 (dq, J= 4.5, 7.2Hz (R1)), 2.18 (app quintet, J = 7.2Hz, 0.4H), 1.66-
1.50 (m, 3H (R1+R2)), 1.38-1.13 (m, 13H (R1+R2)), 0.97-0.84 (m, 13H (R1+R2)); 13C NMR (75 
MHz, CDCl3) δ 189.8, 174.9, 174.8, 173.3, 173.1, 67.7, 66.2, 55.7, 54.0, 51.8, 49.0, 48.9, 47.2, 
43.8, 43.8, 43.6, 42.2, 40.1, 40.0, 39.3, 25.0, 25.0, 24.8, 24.7, 23.6, 23.5, 23.5, 23.4, 21.9, 21.4, 
21.3, 21.0, 15.4, 14.5, 14.4, 14.2, 13.0; HRMS (ES) m/z calcd for C23H34N2O4 (M+Na)+: 
425.2416; found: 425.2431. 
 
 (2R,3S)-Methyl 3-[(2R,3S)-3-amino-2,5-dimethylhexan-amido]-2,5-
dimethyl-hexanoate (46): General Procedure D was followed using 
0.100g of MeO-(30a-30a)-NHC(S)OEt (0.244 mmol) and 0.225g of Oxone® (0.366 mmol).  
0.074 g (97%) of the title compound was obtained as a clear oil.  [a]23D   –58 (c 0.41 CHCl3) IR 
(thin film): 3295, 2956, 1737, 1644, 1545 cm-1, 1H NMR (300 MHz, CDCl3) δ  7.50 (br d, J = 
9.3 Hz, 1H), 4.28–4.19 (m, 1H), 3.66 (s, 3H), 3.06–2.98 (m, 1H), 2.62 (dq, J = 5.1, 7.2 Hz, 1H), 
2.20 (dq, J = 3.6, 7.2 Hz, 1H), 1.72–1.53 (m, 2H), 1.40–1.16 (m, 4H), 1.12 (d, J = 7.2 Hz, 3H), 
1.09 (d, J = 7.2 Hz, 3H), 0.92 – 0.86 (m, 12H);  13C NMR (75 MHz, CDCl3) 175.4, 175.1, 51.6, 
50.4, 48.6,45.7, 44.6, 43.7, 40.8, 25.1, 24.8, 23.5, 23.4, 21.7, 21.7, 12.6, 11.7; HRMS (ES) m/z 
calcd for C17H34N2O3 (M+Na)+: 337.2467; found: 337.2483. 
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 (6S,7R,10S,11R,14S,15R)-Methyl 10,14-diisobutyl-7,11,15-
trimethyl -8,12-dioxo-6-phenethyl-4-thioxo-3-oxa-5,9,13-
triazahexadecan-16-oate (MeO-(30a-30a-30c)-NHC(S)OEt):  General Procedure E was 
followed using 0.213g of 46 (0.677 mmol, 1 equiv) and 0.169g of 30c (0.609 mmol, 0.9 equiv).  
The residue was dissolved in methylene chloride and washed with 1 M HCl.  The organic portion 
was then dried (Na2SO4) and concentrated in vacuo to obtain 0.204 g (57%) of the title 
compound as a yellow solid.  mp: 170 °C (dec); [a]23D   –39 (c 1.3, CHCl3) IR (thin film): 3286, 
2955, 1716, 1649, 1540, 1452, cm-1, 1H NMR (300 MHz, MeOD) 7.85–7.70 (m, 2H), 7.28–7.08 
(m, 3H), 4.70–4.40 (m, 3H), 4.30–4.05 (m, 2H), 3.64 (s, 3H), 2.75–2.15 (m, 5H), 1.85–1.38 (m, 
4H), 1.35–1.22 (m, 4H), 1.20–1.00 (m, 12H), 0.95–0.70 (m, 12H); 13C NMR (100 MHz, 
pyridine-d5) δ 192.0, 191.1, 177.8, 177.6, 175.6, 143.0, 142.4, 129.3, 129.3, 126.7, 67.5, 66.5, 
63.7, 60.8, 58.8, 58.1, 56.0, 55.4, 52.8, 52.1, 49.6, 48.3, 48.0, 47.7, 46.3, 45.5, 45.2, 43.9, 43.8, 
43.6, 42.3, 35.7, 34.8, 34.5, 33.6, 33.5, 30.5, 26.5, 25.8, 24.6, 24.2, 22.0, 16.7, 15.5, 15.2, 14.9, 
14.6, 13.8, 13.6, 8.5; HRMS (ES) m/z calcd for C32H53N3O5S (M+Na)+: 614.3604; found: 
614.3604. 
 
(2R,3S)-Methyl 3-{(2R,3S)-3-[(2R,3S)-3-amino-2-methyl-5 
phenyl-pentanamido]-2,5-dimethylhexanamido}-2,5-dimethyl-
hexanoate (48) General Procedure D was followed using 0.046 g  of MeO-(30a-30a-30c)-
NHC(S)OEt (0.078 mmol) and 0.072 g of Oxone® (0.117 mmol).  0.031 g (80%) of the title 
compound was obtained as a white solid. mp: 180 °C (dec); [a]23D   –45 (c 1.0, CHCl3) IR (thin 
film): 3208, 2955, 1733, 1641, 1544, 1143 cm-1, 1H NMR (400 MHz, CDCl3) 7.48 (br d, J = 9.2 
Hz, 1H), 7.30-7.16 (m, 5H), 6.33 (br d, J = 8.8 Hz, 1H), 4.25-4.18 (m, 1H), 4.12-4.01 (m, 1H), 
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3.68 (s, 3H), 3.01 (app quintet, J = 4 Hz, 1H), 2.75 (m, 1H), 2.65-2.58 (m, 2H), 2.49 (m, 1H), 
2.29 (dq, J = 6.8, 3.2 Hz, 1H) 1.80-1.72 (m, 1H), 1.67-1.20 (m, 7H), 1.15-1.11 (m, 9H), 0.88 (m, 
12H); 13C NMR (75 MHz, CDCl3) δ 175.6, 175.1, 174.0, 141.7, 128.4, 128.2, 125.9, 52.9, 52.8, 
51.7 49.0, 46.0, 45.5, 44.0, 40.9, 40.3, 37.6, 33.1, 29.7, 25.1, 23.6, 21.5, 21.4, 14.2, 13.2, 11.9; 
HRMS (ES) m/z calcd for C29H49N3O4 (M+Na)+: 526.3621; found: 526.3663. 
 
 (6S,7R,10S,11R,14S,15R,18S,19R)-Methyl 14,18-di-
isobutyl-7,11,15,19-tetramethyl-8,12,16-trioxo-6,10-
diphenethyl-4-thioxo-3-oxa-5,9,13,17-tetraazaicosan-20-oate (MeO-(30a-30a-30c-30c)-
NHC(S)OEt): General Procedure E was followed using 0.122g of 48 (0.242 mmol, 1 equiv) and 
0.067g of 30c (0.242 mmol, 1 equiv).  The residue was dissolved in methylene chloride and 
washed with 1 M HCl.  The organic portion was then dried (Na2SO4) and concentrated in vacuo 
to obtain 0.171 g (91%) of the title compound as a yellow solid.  mp: 185 °C (dec); [a]23D  –25 (c 
0.44, CHCl3) IR (thin film):  3281, 2955, 2930, 1717, 1645, 1538, 1454, 1197 cm-1, 1H NMR 
(300 MHz, CDCl3) 7.34-7.05 (m, 10H), 4.57-4.42 (m, 3H), 4.40-4.00 (m, 4H), 3.68 (s, 3H), 3.61-
3.47 (m, 1H), 3.00-2.40 (m, 8H), 2.00-1.45 (m, 6H), 1.39-1.01 (m, 15H), 0.98-0.78 (m, 12H); 
13C NMR (100 MHz, CDCl3) 191.1, 190.3, 190.0, 179.1, 178.3, 178.2, 174.9, 141.3, 140.7, 
128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 126.2, 126.0, 126.0, 68.0, 67.8, 66.5, 66.4, 56.9, 56.6, 
54.3, 54.3, 51.8, 49.1, 43.6, 42.6, 42.5, 42.2, 40.0, 35.5, 34.9, 33.2, 32.7, 32.6, 32.4, 32.0, 29.7, 
25.0, 24.8, 23.6, 23.5, 21.5, 21.3, 14.8, 14.6, 14.2, 14.1, 13.9, 13.5, 13.0, 7.5; HRMS (ES) m/z 
calcd for C44H68N4O6S (M+Na)+: 803.4757; found: 803.4744. 
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(2R,3S)- Methyl 3-((2R,3S)-3-{(2R,3S)-3-[(2R,3S)–3      
amino -2-methyl-5-phenyl- pentanamido] -2-methyl-5-   
phenyl-pentan-amido}-2,5-dimethylhexanamido)-2,5-dimethylhexanoate (49): General 
Procedure D was followed using 0.063g of MeO-(30a-30a-30c-30c)-NHC(S)OEt (0.090 mmol) 
and 0.083g of Oxone® (0.135 mmol).  0.035 g (57%) of the title compound was obtained as a 
yellow solid.  mp: 140 °C (dec); [a]23D   –37 (c 0.61, CHCl3) IR (thin film): 3285, 2955, 2871, 
1732, 1644, 1543, 1454, 1173, cm-1, 1H NMR (300 MHz, MeOD) δ 7.90–7.85 (m, 2H), 7.30–
7.09 (m, 7H), 4.30–4.05 (m, 3H), 3.64 (s, 3H), 2.85–2.20 (m, 9H), 2.05–1.40 (m, 8H), 2.30–1.00 
(m, 14H), 0.93-0.71 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 176.1, 51.5, 50.5, 45.2, 44.4, 24.8, 
23.4, 21.7, 10.8; HRMS (ES) m/z calcd for C41H64N4O5 (M+Na)+: 715.4774; found: 715.4763. 
 
 (7S,8R,11S,12R,15S,16R)-Methyl 7-(ethoxycarbonothioyl 
amino)-11,15-diisobutyl-2,2,8,12,16-pentamethyl-9,13 – di - 
oxo-3,3-diphenyl-4-oxa-10,14-diaza-3-silaheptadecan-17-oate(MeO-(30a-30a-30b) - NHC(S) 
OEt): General Procedure E was followed using 0.040g of 46 (0.127 mmol, 1 equiv) and 0.052g 
of 30b (0.114 mmol, 0.9 equiv).  The residue was dissolved in methylene chloride and washed 
with 1 M HCl.  The organic portion was then dried (Na2SO4) and concentrated in vacuo to obtain 
0.056 g (64%) of the title compound as a yellow solid.  mp: 175 °C (dec); [a]23D   –23 (c 0.32, 
CHCl3) IR (thin film): 3290, 2954, 1710, 1640, 1529, 1374, 1183, 1109cm-1, 1H NMR (300 
MHz, CDCl3)   δ 7.7 (br s, 5H), 7.40 (br s, 5H), 4.70-4.30 (m, 3H), 4.29-4.00 (m, 2H), 3.68 (s, 
3H), 3.03-2.95 (m, 1H), 2.68-2.30 (m, 4H), 2.00-1.45 (m, 8H), 1.40-1.00 (m, 21H), 0.95-0.85 (m, 
12Η); 13C  ΝΜR (75 MHz, CDCl3) δ 191.22, 191.15, 190.65, 190.58, 175.39, 175.20, 174.76, 
174.60, 134.34, 134.18, 130.13, 130.08, 128.36, 128.30, 128.22, 128.09, 66.88, 65.91, 65.73, 
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61.68. 61.38, 55.70, 55.58, 53.22, 51.68, 49.67, 48.98, 47.74, 47.23, 45.19, 45.07, 44.02, 43.22, 
41.77, 36.48, 35.23, 30.03, 27.03, 26.96, 25.63, 25.48, 25.34, 24.34, 23.71, 21.67, 21.56, 19.37, 
16.31, 14.48, 13.13; HRMS (ES) m/z calcd for C42H67N3O6SiS (M+Na)+: 792.4418; found: 
792.4352. 
 
(7S,8R,11S,12R,15S,16R)-Methyl 7-amino-11,15-diisobutyl-
2,2,8,12,16-pentamethyl-9,13-d ioxo-3,3-diphenyl-4-oxa-
10,14-diaza-3-silaheptadecan-17-oate (50): General Procedure D was followed using 0.074g of 
MeO-(30a-30a-30b)-NHC(S)OEt (0.096 mmol) and 0.089g of Oxone® (0.144 mmol). 0.057 g 
(87%) of the title compound was obtained as a yellow solid.  [a]23D   –11 (c 1.0, CHCl3) IR (thin 
film):  3285, 2956, 2931, 1734, 1643, 1544, 1460, 1110 cm-1, 1H NMR (400 MHz, CDCl3) δ 
7.87 (br d, J = 8.8 Hz, 1H), 7.72-7.63 (m, 5H), 7.45-7.36 (m, 5H), 6.40 (br d, J = 9.6 Hz, 1H), 
4.25-4.18 (m, 1H), 4.15-4.07 (m, 1H), 3.76 (t, J = 6 Hz, 1H), 3.71-3.66 (m, 4H), 3.22 (dt, J = 9.6, 
3.2 Hz, 1H), 2.65-2.56 (m, 1H), 2.50-2.43(m, 1H), 2.26 (dq, J = 7.2, 3.2 Hz, 1H), 1.67-1.04 (m, 
26H), 0.90-0.87 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 175.5, 175.1, 173.9, 135.5, 135.4, 
134.8, 133.4, 133.3, 129.7, 129.5, 128.0, 127.7, 127.6, 62.2, 51.7, 51.5, 49.0, 48.9, 45.7, 45.5, 
43.9, 41.1, 41.3, 36.7, 29.7, 29.4, 26.8, 26.5, 25.0, 23.5, 23.1, 21.5, 21.4, 21.2, 19.1, 14.1, 13.1 
HRMS (ES) m/z calcd for C39H63N3O5Si (M+Na)+: 704.4435; found: 704.4423. 
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 (6S,7R,10S,11R,14S,15R,18S,19R)-Methyl 10-[2-(t-
butyl-diphenylsilyloxy)ethyl]-14,18-diisobutyl-7,11,  
15,19-tetra-methyl-8,12,16-trioxo-6-phenethyl-4-thioxo-3-oxa-5,9,13,17-tetraazaicosan-20 –
oate (MeO-(30a-30a-30b-30c)-NHC(S)OEt): General Procedure E was followed using 0.045 g 
of 50 (0.066 mmol, 1 equiv) and 0.016g of 30c (0.059 mmol, 0.9 equiv). The residue was 
dissolved in methylene chloride and washed with 1 M HCl.  The organic portion was then dried 
(Na2SO4) and concentrated in vacuo to obtain 0.045 g (80%) of the title compound as a yellow 
solid. mp: 125 °C (dec); [a]23D   –53.9 (c 3.30, CHCl3) IR (thin film): 3281, 2955, 1719, 1640, 
1542, 1455, 1110 cm-1, 1H NMR (400 MHz, MeOD) δ 7.87-7.78 (m, 2H), 7.75-7.63 (m, 3H), 
7.42-7.37 (m, 5H), 7.23-7.13 (m, 5H), 4.45-4.42 (m, 2H), 4.25-4.02 (m, 3H), 3.64 (s, 3H), 2.77-
2.22 (m, 8H), 1.98-1.40 (m, 8H), 1.34-0.85 (m, 36H); 13C NMR (75 MHz, CDCl3) δ 176.1, 51.5, 
50.5, 45.2, 44.4, 24.8, 23.4, 21.7, 10.8; HRMS (ES) m/z calcd for C54H82N4O7SiS (M+Na)+:  
981.5571; found: 981.5506. 
 
 (7S,8R,11S,12R,15S,16R)-Methyl 7-((2R,3S)-3-amino -
2-methyl-5-phenylpentanamido)-11,15-diisobutyl-2,2,8,  
12,16-pentamethyl-9,13-dioxo-3,3-diphenyl-4-oxa-10,14-diaza-3-silahepta-decan-17-oate 
(51):  General Procedure D was followed using 0.155g of MeO-(30a-30a-30b-30c)-NHC(S)OEt 
(0.161 mmol) and 0.149g of Oxone® (0.242 mmol).  0.121 g (86%) of the title compound was 
obtained as a yellow solid.  mp: 115°C (dec); [a]23D   –28 (c 0.35, CHCl3) IR (thin film): 3284, 
2956, 1735, 1644, 1542, 1455, 1110 cm-1, 1H NMR (400 MHz, MeOD) δ 7.72-7.50 (m, 5H), 
7.42-7.32 (m, 5H), 7.22-7.05 (m, 5H), 4.25-4.02 (m, 3H), 3.64 (s, 3H), 2.80-2.20 (m, 9H), 2.00-
1.30 (m, 10H), 1.28-0.85 (m, 33H); 13C NMR (100 MHz, MeOD) δ 177.3, 176.9, 137,4, 136.8, 
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136.1, 135.0, 131.0, 130.6, 129.7, 129.5, 129.1, 129.0, 128.7, 127.3, 52.4, 45.9, 44.0, 42.7, 27.5, 
27.3, 26.3, 24.6, 24.1, 21.9, 21.7, 20.1, 16.3, 16.1, 13.5, 13.3, 13.1; HRMS (ES) m/z calcd for 
C51H78N4O6Si (M+Na)+: 893.5588; found: 893.5513. 
 
(4S,5R)-Benzyl-4-((ethoxycarbonothioyl)amino)-6-(((2R,3S)- 1- 
methoxy-2,5-dimethyl-1-oxohexan-3-yl)amino) -5-methyl-6-oxo-
hexanoate (MeO-(30a-30e)-NHC(S)OEt): General Procedure E was 
followed using 0.090 g of 45 (0.521 mmol, 1 equiv) and 0.175 g of 30e (0.521 mmol, 1 equiv). 
The residue was dissolved in methylene chloride and washed with 1 M HCl.  The organic portion 
was then dried (Na2SO4) and concentrated in vacuo to obtain 0.109 g (42%) of the title 
compound as pale yellow solid.  mp 114-118 ºC; [α]23D   –50 (c 1.4, CHCl3); IR (thin film): 3305, 
2956, 1736, 1648, 1529, 1453, 1381, 1263, 1176, 1142 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.33 
(s, 5H), 7.10 (dd, J = 9.6, 3.6 Hz, 0.8H), 6.00 (d, J = 9.3 Hz, 0.8H), 5.09 (s, 2H), 4.50 (q, J = 6.9 
Hz, 1H), 4.41 (q, J = 7.2 Hz, 1.4H), 4.27-4.13 (m, 1.2H) 3.67 (s, 3H), 2.78-2.69 (m, 0.6H), 2.67-
2.56 (m, 1.1H), 2.52-2.30 (m, 2.5H), 2.07-1.92 (m, 0.8H), 1.91-1.74 (m 1H), 1.60-1.47 (m, 1H), 
1.32-1.15 (m, 8.5H), 1.13 (d, J = 7.2 Hz, 3H), 0.88 (dd, J = 2.4, 6.6 Hz, 6H); 13C NMR (125 
MHz,CDCl3) δ  190.4, 190.1, 174.8, 174.8, 173.1, 172.9, 172.8, 135.8, 135.7, 128.5, 128.3, 
128.2, 128.2, 67.8, 66.5, 66.3, 66.3, 60.3, 57.1, 55.2, 51.8, 51.8, 49.1, 49.1, 46.1, 43.6, 43.6, 40.1, 
40.0, 30.9, 27.4, 25.3, 25.0, 23.4, 21.4, 21.4, 21.0, 15.4, 14.5, 14.4, 14.1, 12.9, 12.9, 12.8; HRMS 
(ES) m/z calcd for C26H40N2O6NaS (M+Na)+: 531.2505; found: 531.2487. 
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 (4S,5R)-Benzyl 4-amino-6-(((2R,3S)-1-methoxy-2,5-dimethyl-1-oxo-
hexan-3-yl)amino)-5-methyl-6-oxohexanoate (52): General Procedure 
D was followed using 0.052 g of MeO-(30a-30e)-NHC(S)OEt (0.102 
mmol) and 0.094 g of Oxone® (1.5 mmol).  The crude product was extracted with 1M HCl(aq), 
and the aqueous layer was basified to pH 10 with NaOH, then extracted with ethyl acetate (3 x 
10mL).  The organic layer was then dried (Na2SO4) and concentrated.  0.037 g (88%) of the title 
compound was obtained as a clear oil.  1H NMR (500 MHz, CDCl3) 7.37-7.30 (m, 5H), 7.10 (d, J 
= 9.5 Hz, 1H), 5.11 (s, 2H), 4.25-4.18 (m, 1H), 3.66 (s, 3H), 2.95 (app p, J = 4.0 Hz, 1H), 2.613 
(dq, J = 7, 4.5 Hz, 1H) 2.52- 2.38 (m, 3H), 2.22 (dq, J = 7.5, 4 Hz, 1H), 1.80-1.74 (m, 1H), 1.66-
1.52 (m, 5H), 1.36-1.27 (m, 2H), 1.24-1.56 (m, 4H), 1.10 (dd, J = 7.5, 5 Hz, 6H), 0.89 (dd, J = 
6.5, 4 Hz, 6H);  13C NMR (125 MHz, CDCl3) δ 175.0, 175.0, 173.2, 135.82, 128.5, 128.5, 128.2, 
128.2, 66.3, 52.4, 51.7, 48.7, 45.9, 43.6, 40.6, 31.6, 30.7, 25.1, 23.4, 21.6, 12.6, 11.6;  HRMS 
(ES) m/z calcd for C23H37N2O5 (M+)+: 421.2702; found: 421.2684. 
 
 
(6S,7R,10S,11R,14S,15R)-Methyl 6-((1-benzyl-1H-indol-3-
yl)methyl)-10-(3-(benzyloxy)-3-oxopropyl)-14-isobutyl 7,11, 
15-trimethyl-8,12-dioxo-4-thioxo- 3-oxa-5,9,13- triazahexa 
decan-16-oate (53): General Procedure E  was followed using 0.037 g of 52 (0.088 mmol, 1 
equiv) and 0.035 g of 19f (0.088 mmol, 1 equiv).  The reaction mixture was concentrated and 
triturated with hot hexanes and filtered.  The title compound was obtained in 42% yield (0.030 g) 
as a white solid.  mp 182-188 ºC; [a]23D   -37 (c 1.5, CHCl3); IR (thin film): 3286, 2959, 1736, 
1646, 1538, 1453, 1377, 1264, 1172 cm-1; 1H NMR (500 MHz, pyridine-d5 w/ TMS) δ 10.21 (d, 
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J = 9.5 Hz, 0.3H), 10.15 (d, J = 9.5 Hz, 0.5H), 9.19 (d, J = 9 Hz, 0.3H), 9.00 (d, J = 9 Hz, 0.4H), 
8.64 (t, J = 8 Hz, 0.8H), 8.24-8.23 (m, 0.3H), 8.02-8.00 (m, 0.4H), 7.39-7.10 (m, 16H), 5.61 (dq, 
J = 8.5, 4 Hz, 0.5H), 5.24-5.10 (m, 6H), 4.94-4.86 (m, 1H), 4.84-4.77 (m, 1H), 4.55-4.48 (m, 
1H), 4.36-4.33 (m, 0.4H), 4.25-2.22 (m, 0.4H), 3.77 (dd, J = 4, 15 Hz, 0.5H), 3.70 (s, 1.5H), 
3.69 (s, 1.5H), 3.60 (dd, J = 14.5, 8 Hz, 0.5H), 3.35 (t, J = 7.5 Hz, 0.4H), 3.19 (dd, J = 14, 10 Hz, 
0.4H), 3.08-2.89 (m, 2H), 2.84-2.77 (m, 1.5H), 2.72 (m, 0.6H), 2.50-2.45 (m, 0.8H), 2.36-2.28 
(m, 0.9H), 1.95-1.90 (m, 0.9H), 1.64-1.58 (m, 5.7H), 1.30 (dd, J = 3, 7 Hz, 3.5H), 1.1 (t, J = 
7.5Hz, 1.3H), 1.0 (t, J = 6 Hz, 2.5H), 0.87 (dd, 6.5, 2 Hz, 2.5H), 0.71 (t, J = 7 Hz, 1H); 13C NMR 
(125 MHz, pyridine-d5 w/ TMS) δ 191.7, 191.0, 176.1, 175.9, 175.8, 175.5, 175.4, 173.8, 173.7, 
139.2, 139.1, 137.6, 137.5, 137.4, 137.4, 130.2, 129.8, 129.6, 129.4, 129.3, 129.3, 128.9, 128.8, 
128.8, 128.8, 128.3, 128.2, 128.1, 128.1, 127.8, 127.7, 122.5, 122.4, 120.5, 120.4, 120.1, 119.9, 
112.7, 112.6, 110.7, 67.0, 66.7, 66.1, 59.0, 57.4, 52.3, 52.1, 50.3, 49.7, 47.3, 47.0, 45.6, 45.4, 
42.2, 32.5, 30.9, 29.6, 29.5, 28.1, 25.9, 24.2, 22.0, 17.7, 16.9, 16.9, 16.7, 14.9, 14.2, 13.6, 13.5; 
HRMS (ES) m/z calcd for C46H60N4O7NaS (M+Na)+: 835.4080; found: 835.4110. 
 
(2R,3S)-Methyl 3-((2R,3S)-3 (methoxycarbonothioylamino)- 2 -
methyl -5-phenylpentanamido)-2-methyl-5-phenylpentanoate (54) 
General procedure E was followed using 61 mg of compound 30c (0.277 mmol, 1 equiv) and 77 
mg of compound (MeO-(30c)-NH2) (0.277 mmol, 1 equiv)  The solvent was removed in vacuo 
and the crude material was purified by flash chromatography (50% EtOAc/ hexanes on silica gel) 
to afford 47 mg (34%) of the title compound as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.82-7.09 (m, 15H), 4.59-4.40 (m, 5H), 4.24-4.15 (m, 2.5H), 3.67 (s, 1.5H), 3.63 (s, 3H), 2.81-
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2.52 (m, 11.6), 2.0-1.6 (m, 9H), 1.37-1.33 (m, 3H), 1.26 (app. t, J = 3.3 Hz, 5 H) 1.19-1.13 (m, 
11H) 
 
(2R,3S)-3-((2R,3S)-3-(Methoxycarbonothioylamino)-2-methyl- 5 -
phenylpentanamido)-2-methyl-5-phenylpentanoic acid (55)  50 
mg (0.10 mmol) of 54 was stirred in MeOH:THF:H2O (2:6:1) (0.07M).  42 mg (1.0 mmol, 10 
equiv) of LiOH was added to the solution and was stirred for 12 hrs at rt.  Saturated ammonium 
chloride was added to the solution until a pH of 6 was obtained.  The aqueous solution was 
extracted with 5: 1 chloroform: isopropanol (3 x 5 mL).  The organics were dried with anhydrous 
Na2SO4 and concentrated to afford 46 mg (96%) of the title compound as a white solid. 1H NMR 
(300 MHz, CDCl3) δ 7.25-7.04 (m, 10H), 4.54-4.43 (m, 2H), 4.25-4.05 (m, 2H), 2.72-2.55 (m, 
7H), 1.94-1.70 (m, 5H), 1.34-1.11 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 190.3, 189.9, 178.9, 
174.1, 173.5, 141.3, 141.1, 141.0, 140.8, 128.4, 128,4, 128.3, 126.1, 126.0, 125.9, 68.0, 66.5, 
57.2, 55.2, 50.9, 50.8, 46.5, 43.6, 43.4, 43.3, 34.7, 32.8, 32.6, 32.4, 32.3, 29.7, 15.2, 15.0, 14.2, 
14.1, 13.3, 13.1, 12.9  
 
(6S,7R,10S,11R,14S,15R,18S,19R)- Methyl 
14,18-diisobutyl-7,11,15,19- tetra-methyl-
8,12,16 -trioxo-6,10-diphenethyl-4-thioxo-3-
oxa-5,9,13,17-tetraazaicosan-20-oate (56): In 0.30 mL of DMF was solvated 21 mg (0.043 
mmol) of 55 (0.14M).  To the solution was added 16 mg (0.043 mmol, 1 equiv.) HATU and 
0.015 mL (0.086 mmol, 2 equiv.) of iPr2NEt.  After stirring at rt for 30 min, a solution of 16 mg 
(0.043 mmol, 1 equiv) of 46 in 0.20 mL (0.22M) DMF was added dropwise over 10 min.  The 
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solution was stirred at rt for 48 hrs.  To the solution was added saturated ammonium chloride and 
extracted with 5:1 chloroform: isopropanol (3 x 2 mL).  The organics were combined and dried 
with anhydrous Na2SO4.  The mixture was filtered and concentrated in vacuo to afford 0.022g 
(65%) of title compound as a yellow solid.   
 
General Procedures F:  Solid Support Synthesis of β-Amino Acid Oligomers:   
 
 
Coupling of β-Amino Acids: To a heterogeneous solution of resin in DMF was added 
thiazinone or β-lactam solvated in DMF.  The heterogeneous solution was stirred at room 
temperature for 24 hours.  When the reaction was complete, the solvent was removed via 
vacuum filtration followed by 3 rinses with DMF.   
 
 
 
Removal of thiocarbamate group:  To a heterogeneous solution of resin in 1:1 dioxane 
and H2O was added Oxone (1.5 equiv).  The heterogeneous solution was stirred at room 
temperature for 2 to 4 hours.  Upon complete reaction, the solvent was removed via vacuum 
filtration, 3 rinses with H2O and 3 rinses with DMF.  
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Cleavage of compound from resin:  Prior to cleavage, the resin was rinsed multiple 
times with acetonitrile.  To dry resin after acetonitrile washes, was added a 95% TFA solution 
(95% TFA, 2.5% Et3SiH, 2.5% H2O) at room temperature.  When cleavage was complete the 
TFA solution was collected via vacuum filtration, followed by 3 rinses with ACN.  The collected 
TFA and ACN filtrates were combined and concentrated to afford pure compound.  To ensure 
complete recovery of material, the resin was resubjected to cleavage conditions.   
 
O-Ethyl ((2R,3S)-1-(((2R,3R)-1-(((2R,3S)-1-amino- 2,5-
dimethyl-1-oxohexan-3-yl)amino) -2,5- dimethyl-1- oxo  
hexan-3-yl)amino)-2,5-dimethyl-1-oxohexan-3-yl)carbamothioate (58): General procedures A 
and B were followed for each β-amino acid addition starting with 0.119g of resin (0.044mmol).  
After 3 iterations of procedures A and B, without the final deprotection of the trimer, general 
procedure C was followed, providing 58 in 87.0% yield (0.020g, 0.039mmol) of pale yellow 
solid. 
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O-Ethyl ((2R,3S)-1-(((2R,3R)-1-(((2R,3S)-1- amino-2 -
methyl -1-oxo-5-phenylpentan-3-yl)amino) -2-methyl-1-
oxo-5-phenylpentan-3-yl)amino) -2-methyl-1-oxo- 5-
phenylpentan-3-yl)carbamothioate (57): General procedures A and B were followed for each 
β-amino acid addition starting with 0.235g (0.087mmol) of resin.  After 3 iterations of 
procedures A and B, without the final deprotection of the trimer, general procedure C was 
followed, providing 57 in 95.7% yield (0.056g, 0.083mmol) as a white solid.   
 
O-Ethyl ((2R,3S)-1- (((2R,3S)-1-(((2R,3S)-1 -
(((2R,3S)-1-amino-2,5- dimethyl-1-oxohexan- 3-
yl)amino)-2,5-dimethyl-1-oxohexan-3-yl)amino)-
2-methyl-1-oxo-5-phenylpentan-3-yl)amino)-2-methyl-1-oxo-5-phenylpentan-3-yl)carbamo- 
thioate (59): General procedures A and B were followed for each β-amino acid addition starting 
with 0.235g of resin (0.087mmol).  After 3 iterations of procedures A and B, without the final 
deprotection of the trimer, general procedure C was followed, providing 59 in 52.6% yield 
(0.035g, 0.0457mmol) as a yellow solid.  
 
(2R,3S)-3-((Ethoxycarbonothioyl)amino)-2,5-dimethylhexanoic  acid 
(60): To a solution of O-ethyl ((2R,3S)-1-amino-2,5-dimethyl-1-oxohexan-
3-yl)carbamothioate (0.050g, 0.203mmol) in AcOH and Ac2O (1:2) at 0ºC was added 1 portion 
of NaNO2 (0.175g, 2.03mmol) stirred for 30 minutes at 0ºC and another portion of NaNO2 
(0.175g, 2.03mmol) was added.  The solution was warmed to room temperature over 10 hours.  
To the solution was added aqueous NaHCO3 to a pH of 8 and extracted with 5:1 chloroform: 
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Isopropyl alcohol.    The organics were dried and 60 was isolated in a 62% yield (0.031g, 
0.126mmol) as a white solid. IR (thin film): 3400, 2960, 2874, 1742, 1710, 1528, 1466, 1374, 
1314, 1278, 1178 cm-1 1H NMR (500 MHz, CDCl3) δ 4.55-4.51 (q, J=7 Hz, 2H), 4.30-4.26 (m, 
0.5H), 4.13-4.06 (m, 0.5H), 3.14-3.07 (m, 1H), 2.04-1.98 (m, 4H), 1.46-1.43 (m, 3.5H), 1.38-
1.31 (m, 1H), 1.27-1.24 (m, 3H), 0.96 (d, J=6.5Hz, 1H), 0.92 (d, J=7Hz, 3H), 0.80 (d, J=6.5Hz, 
3H), 0.76 (d, J=6.5Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 169.9, 166.4, 165.9, 64.5, 53.7, 47.0, 
43.0, 43.0, 39.0, 25.5, 25.3, 25.2, 23.3, 22.5, 22.2, 22.2, 21.2, 15.0, 14.4, 14.3, 14.2, 8.6 
 
O-Ethyl ((3S,4R)-6-diazo-4- methyl-5-oxo-1-phenylhexan-3-yl) carbamo-
thioate (61):  To a 2M solution of TMSCHN2 in Ether (0.216 mL, 0.432 mmol) 
was added 30c (0.100 g, 0.360 mmol) in THF (3.6 mL, 0.1M) at - 78ºC.    To 
that solution was added NaN(TMS)2 (0.432 mL, 0.432 mmol in 1 M in THF).  This solution was 
allowed to stir at - 78ºC for 1 hour.  To the solution was added 2 mL Et2O followed by 2 mL of 
H2O.  The solution was extracted with three portions of Et2O.   Flash Column Chromatography 
was run with 20% EtOAc/ hexanes and 0.076 g (66% yield) of title compound was isolated as a 
yellow oil.  IR (thin film): 3258, 2977, 2928, 2106, 1628, 1528, 1453, 1378, 1203, 1178 cm-1 1H 
NMR (500 MHz, CDCl3) δ 7.31-7.15 (m, 10H), 6.92 (s, 0.8H), 6.65 (s, 1H), 5.32 (s, 1H), 5.25 (s, 
0.8H), 4.57 (dq, J=1.5, 7 Hz, 2H), 4.54-4.45 (m, 4H), 4.16-4.12 (m, 1.5H), 2.88 (br s, 1H), 2.78-
2.72 (m, 2.5H), 3.69-2.63 (m, 1.5H), 2.61-2.55 (m, 1H), 2.48 (br s, 0.8H), 1.96-1.88 (m, 3.7H), 
1.72-1.67 (m, 1.5H), 1.34 (t, J=7 Hz, 6H), 1.18 (d, J=7.5 Hz, 3H), 1.15 (d, J=7 Hz, 2.4H); 13C 
NMR (125 MHz, CDCl3) δ 196.6, 195.6, 190.3, 190.2, 141.3, 140.7, 128.5, 128.4, 128.4, 128.3, 
126.1, 126.0, 68.0, 66.4, 60.4, 57.6, 55.1, 55.0, 49.3, 47.3, 34.2, 32.7, 32.4, 14.3, 14.2, 14.1, 13.9  
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(3S,4S)-4-((Ethoxycarbonothioyl)amino)-3-methyl-6-phenyl hexanoic 
acid (62):  To a solution of 61 in THF:H2O (10:1, 0.252mL) wrapped in 
foil at -25 ºC.  PhCO2Ag (0.002g, 0.0069mmol)      in Et3N (0.026mL, 
0.186 mmol) was added to the solution and allowed to slowly come to room temperature in bath 
over 3 hours.  The solution was concentrated and flash column chromatography was done with 
20% ETOAc/ hexanes to obtain 0.008 g (41% yield) of the title compound was obtained as a 
clear oil. 1H NMR (500 MHz, CDCl3) δ 7.30-7.18 (m, 5H), 4.71 (dt, J=4, 7 Hz, 1H) 4.58 (dq, J= 
4, 7 Hz, 2H) 2.74-2.66 (m, 2H), 2.64-2.56 (m, 2H), 2.44-2.38 (m, 1H), 2.08-2.03 (m, 1H), 2.01-
1.94 (m, 1H), 1.42 (t, J=7 Hz, 3H), 1.20 (d, J=6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
188.2, 171.4, 141.4, 128.5, 128.2, 126.1, 68.3, 64.7, 40.2, 33.3, 31.0, 30.8, 14.4, 13.7  
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